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PREFACE 
 
This dissertation is presented in a format of manuscripts. The findings of the study are presented 
in chapters 3 and 4 in a manuscript format as required by the new regulations of the University of 
KwaZulu-Natal. A systematic review protocol has been submitted for publication to the journal 
BMC Systematic Reviews. Two manuscripts emanated from data collected.  One of the two 
manuscripts has been submitted for publication to the African Journal of Biomedical Research. 
Another manuscript has been submitted for publication to the journal BMC Complementary and 
Alternative Medicine. The reference list is cited according to the instructions for authors as 
required by the journals where manuscripts have been submitted and according to the required 
reference style of each journal. A complete reference list is included at the end of chapter one and 
the synthesis chapter.  
The dissertation consists of 5 chapters as follows: 
 Chapter 1: Provides a background and a brief overview of literature of the proposed study. 
This chapter highlights an overview of the rational of the study, research questions, the aim, 
and objectives of the study. A general methodology has been included to achieve aim and 
different objectives of the study. 
 Chapter 2: Consists of a systematic review protocol submitted to Bio Med Central, Systematic 
review journal under the title “Mapping evidence of collaboration between traditional health 
practitioners and biomedically trained healthcare professionals in the reduction of 
antimicrobial resistance in sub-Saharan Africa: A systematic review protocol”. 
 Chapter 3: Provides an original manuscript article submitted to the African Journal of 
Biomedical Research, under the title “Perspectives on the concurrent use of traditional and 
prescribed antimicrobial medicines for infectious diseases: a triangulation study involving 
biomedically trained healthcare professionals, outpatients, traditional health practitioners and 
their patients 
 Chapter 4: Comprises an original manuscript article submitted to the journal BMC 
Complementary and Alternative medicine under the title “Evaluation of concomitant use of 
prescribed antiviral, antibacterial and/or antifungal medicines with traditional medicine in 
Ilembe district, South Africa: A medical chart review”. 
 Chapter 5: Provides the synthesis which includes general conclusions, strengths and 
limitations of the study then recommendations.  
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GENERAL ABSTRACT 
  
Background: Traditional herbal mixtures are generally available, affordable and commonly 
utilized in developing and developed countries and usually utilized as self-care treatments. 
However, its incorrect use can lead to fatal outcomes. Antimicrobial resistance (AMR) is driven 
by many factors such as the careless use of prescribed antimicrobial medicines and the use of 
traditional medicine, with the result that there is always the danger of misadministration, 
interaction, and toxicity. AMR is also considered as the major cause of treatment failure and is 
largely responsible for the declining in eradication rates of infectious diseases worldwide. 
Individuals may consult both traditional healer practitioners (THPs) and biomedically trained 
healthcare professionals (BHPs) for the treatment of their bacterial and viral infections. This study 
aimed at determining whether any antimicrobial resistance and treatment failure could occur 
among patients, attending outpatient departments of selected healthcare facilities, who used 
concurrently prescribed antimicrobial medicines and traditional medicine in the Ilembe district, 
South Africa 
Methods: This study was a cross-sectional descriptive study using a mixed method approach. 
First phase was a qualitative study using an interview face to face with a questionnaire. One 
hundred and thirty two respondents were included with four (4) types of participants: Traditional 
health practitioners (THPs), Patients seen by THPs, biomedically healthcare professionals (BHPs) 
and outpatients. Second phase was a quantitative study using a medical chart review of 400 
patients’ medical records and who attended the outpatient department in two public healthcare 
facilities between February and March 2018. Antimicrobials prescribed alone or in association 
with other medicines and concurrent use of traditional medicine were assessed and reported using 
descriptive statistics. Where applicable, associations were carried out; a p-value ˂0.05 was 
estimated as statistically significant. 
Results: This study found a small number of medicinal plants used by traditional healer 
practitioners for treating infectious diseases of patients seen by them. The majority of traditional 
healer practitioners and their patients (21/32, 65.62%) mixed different herbs for the treatment of 
infectious diseases. Traditional healer practitioners and patients seen by them agreed that the 
combination of both traditional medicines and prescribed medicines for infectious diseases may 
lead to interactions, adverse effects; infectious diseases may get worse if the time lapses between 
the two medicines do not exist. However, biomedically healthcare professionals and outpatients 
reported that combing traditional with prescribed medicines for infectious diseases may result in 
drug resistance, especially resistance to antibiotics and they highlighted that the majority of 
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patients came to the clinic with several complications such as kidney failure, vomiting, diarrhoea 
and jaundice after using either TM alone or in combination with prescribed medicines.  
Besides the perception phase of this study, 400 outpatients’ medical records were documented 
from two different municipalities, many participants had viral infections (194/400, 48.50%). 
Overall, 12% of participants (48/400) had documented negative clinical outcomes with adverse 
effects (30/48) and interactions (18/48). A few participants (15/400, 3.75%) had used traditional 
medicine in conjunction with prescribed medicines. Among those who used both traditional 
medicine and prescribed medicines, the majority (80%, 12/15) had documented adverse effects 
due to the concurrent use of traditional medicine and prescribed medicines. After adjustment, 
documented adverse effects and interactions were significantly more likely due to the use of 
traditional medicine (AOR = 0.01, 95% CI = 0.001-0.05) and (AOR = 0.21, 95% CI = 0.37-1.23) 
respectively. 
Conclusion: From perceptions stated by respondents in this study, the concurrent use of 
conventional and traditional herbal medicines may interfere or result in damaging some organs, 
failure of therapeutic effects and modification of pharmacological actions of administered 
medicines. Traditional medicine was sparingly used in conjunction with prescribed antimicrobials 
for viral and bacterial/fungal infectious diseases. However, adverse effects and interactions such 
as herbal intoxication, persistent rashes, and treatment failure were documented in few medical 
chart records among outpatients attending the two selected healthcare facilities. Further studies 
are needed to investigate the effects of concurrent use of traditional medicine and prescribed 
medicines in other parts of South Africa.  
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CHAPTER 1: INTRODUCTION  
 
 
This chapter provides a background and a brief overview of literature of the proposed study. It 
includes the rational of the study, research questions, the aim, and objectives of the study. A 
general methodology has been included to achieve aim and different objectives of the study. 
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1.1 Background 
Antibiotic-resistant microorganisms  is considered as nightmare bacteria that pose disastrous 
threat to people  around the world (WHO, 2013). Infections from resistant bacteria are currently 
common; some pathogens have become resistant to multiple classes of antimicrobial medicines 
(Ledingham and Warrell, 2000). Antimicrobial resistance is a microbial adaptation which allows 
microbes to persist despite the presence of the antibiotic or antiviral and which reduce the 
potential human health benefit derived from antibiotics and/or antiviral medicines (Hunt et al., 
2013).  
Antimicrobial drug resistance is a major  cause of treatment failure and is largely responsible for 
the declining in eradication rates (Megraud, 2007). According to World Health Organization 
(WHO)  infectious and non-infectious diseases are invariably treated with antibiotics and this 
poor practice is leading to the inappropriate use of antimicrobials (WHO, 2011). Viruses and 
bacteria cause a significant proportion of infections in Africa; the WHO reported that bacterial 
infections death rate has been estimated at 45% in Africa and South-East Asia (WHO, 2014)  
while they were reported to be  responsible for 48% of premature deaths worldwide (Sosa et al., 
2009). According to the Joint United Nations Programme on HIV(Human immunodeficiency 
virus) and AIDS (Acquired immune deficiency syndrome) (UNAIDS, 2014), 69% of HIV 
infected people are living in Sub-Sahara Africa and since 2000, about 25.3 million deaths of 
people living with HIV/AIDS (PLWA) were registered in the world.   
 
South Africa is not an exception to wide spread of antimicrobial resistance. It has been  faced 
with a high burden of antimicrobial resistance such as  drug resistant tuberculosis, drug resistant 
HIV and antibiotic resistance (Hunt et al., 2013).   HIV infection is reported to be  responsible for 
the high   rate of deaths 31.2%  in the total of 6.4 million of PLWA (People Living with 
HIV/AIDS)   in South Africa (Shisana et al., 2014); however the rate of PLWA increased from 
6.8 million in 2014 (UNAIDS, 2014) to 7.52 million in 2018 (Statistics, 2018). A report of WHO 
has shown that 30% of bacteria were resistant to common antibiotics used to treat bacterial 
infectious diseases (WHO, 2014). The problem of antimicrobial resistance is extremely serious, 
some bacteria and viruses are becoming  resistant because there is either only antimicrobial of 
last resort or infections are untreatable (Galea, 2015). Antimicrobial resistance (AMR) in South 
Africa is driven by many factors which include the careless use of   prescribed antimicrobial 
medicines and the use of traditional medicine (TM), with the result that always the danger of 
misadministration, interaction and toxicity can happen (Goff et al., 2017, Fennell et al., 2004). 
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Traditional medicine has been defined by the WHO  as "the sum total of the knowledge, skills, 
and practices based on the theories, beliefs, and experiences indigenous to different cultures, 
whether explicable or not, used in the maintenance of health as well as in the prevention, 
diagnosis, improvement or treatment of physical and mental illness (WHO, 2004)."  Thus, Plants 
are considered as one of the most promising sources for new antimicrobial medicines discovery 
(ATMs); more than hundreds of plants in the world are used in TM as primary health care needs 
by up to 80% of the population in Asia, Africa, Latin America and the middle-East for the 
treatment   of virus and bacterial infections (Yuan et al., 2016, Mukul et al., 2016, Fyhrquist et 
al., 2002). In the European Union, 100 million people believed also in the use of TM (WHO, 
2011).   
It is estimated that approximatively 27 million South Africans, including PLWA and bacteria 
infected patients still rely  on traditional medicine for their primary health care needs (Street et 
al., 2008). It is relatively due to good accessibility of plants, affordability, confidentiality of health 
information between the patient and  practitioner (Hoyler et al., 2018, Ballabh et al., 2008); 
medicinal plants are also believed to fight  against specific symptoms evenly diseases such as  
weight loss, skin disorders, lack of energy, lack of appetite, diarrhea, nausea and vomiting, 
treatment of side effects of antiretroviral medicines (ARVs) as well as dizziness, fungal infections, 
pain and stomach upsets (Petzer and Mngqundaniso, 2008, Richter, 2004). 
McLay et al., (2017) reported that 44.9% of the study participants have used concurrently 
traditional medicine with different prescribed medicines. Of whom, 12.7% women with the 
potential to increase the risk of postpartum haemorrhage, alter maternal haemodynamics, and 
enhance maternal/fetal central nervous system depression (McLay et al., 2017). Furthermore, 
another study revealed that less than 20% of participants co-used TM and ARV (Hughes et al., 
2012). In addition, 45% of participants in a study were co-users of conventional drugs and herbs, 
while a sizable proportion of the General Practitioner’s patients who co-used herbs with 
conventional drugs reported interaction potential or additive effects like anticoagulants and garlic. 
The low disclosure of herbal use to their General Practitioner, poly herbacy and the risk of 
interactions in vulnerable groups like elderly and chronically ill patients, warrant increased 
awareness among General Practitioners (Djuv et al., 2013). 
TM is commonly used in combination with conventional medicines, mostly with satisfactory 
results but in some case, the effect of the two associated treatments may be magnified, interacted 
and/or opposed (Duru et al., 2016, Fugh-Berman, 2000). Different patient groups are known to 
use herbal remedies and conventional drugs concomitantly (co-use). This causes a serious risk of 
herb-drug interaction through altering the drug’s pharmacokinetics or pharmacodynamics. Little 
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information have been reported in literature regarding the co-use among patients in general 
practice.  Patients used TM concurrently with conventional medicine and thus interactions might 
pose a risk at any step of absorption, distribution and elimination phases of the pharmaceutical 
disposition, which could affect the pharmacokinetic of the medicine in the body (Müller and 
Kanfer, 2011). Medicinal Plants  such as  Taraxacum officinale, Echinacea purpurea,  Hypoxis 
hemerocallidea, Moringa oleifera, and Lessertia frutescens induce the inhibition of  the 
cytochrome CYP450 enzymes which can modify the metabolism of  antibacterial (ATB) or ARVs  
and leading to lack of efficacy and adverse effects experienced by  PLWA as well as to those who 
using simultaneously TM  with ARVs (Mills et al., 2005, Müller and Kanfer, 2011).  
Individuals may consult both Traditional Healer practitioners (THPs) and biomedically trained 
healthcare professionals (BHPs) for bacterial and viral infections. However, a limited knowledge 
of interactions remains about the concurrent use of TM and prescribed medicines for bacterial 
and viral infections.  
 
1.2 Literature review 
This is a brief overview of the literature. Relevant literature review has been included in each of 
manuscripts included in this dissertation. 
1.2.1 Concepts on Antimicrobial resistance (AMR) 
1.2.1.1 Definition 
After the use of antimicrobials in human medicine and animal manufacturing, the pressure of 
selection increased and resistance genes were produced in various bacterial groups (JETACAR, 
1999). Microorganisms change over time so that they can defend themselves against the harmful 
effects of medicine (Davies, 1994). This protection inevitably leads to drug resistance, certainly 
due to the human use of antibiotics, and consequently they produce compounds that  lead to the 
development of resistance as a means of survival in the presence of their own products and 
conflicting species; microbial resistance occurs when antibiotic-inactivating enzymes appear, 
which can modify the structure of receptors, improve efflux through medicine transporters and 
reduce cell wall permeability to antimicrobials (Trevor et al., 2010). 
 
1.2.1.2 Emergency of AMR  
After sulphonamides were introduced in 1937, the appearance of specific resistance mechanisms 
was shown to be the first effective antimicrobials (ATMs) (Kampmeier, 1983) but after few years 
in 1940, Abraham and Chain identified penicillinase (enzyme) several years before the use of 
penicillin as a therapeutic compound. S. Pneumococcus aureus pneumonia was the first bug 
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discovered against penicillin thereafter, Enterococcus faecium bacterium that caused intestinal 
infection in 1983 was finally considered also as one of the bugs that outwitting penicillin (Lewis, 
1995). Streptomycin was found arising during the treatment when introduced for the treatment of 
mutant strains of Mycobacterium tuberculosis resistant to therapeutic concentrations of the 
antibiotic and to the treatment of tuberculosis (Shah et al., 2007). After the rapid emerging 
resistance of penicillin for the treatment of infections caused by organisms intrinsically resistant 
to penicillin, chloramphenicol, erythromycin and vancomycin were finally introduced (Klugman, 
1994).   
 
1.2.1.3 Factors contributing to AMR  
In the development of antimicrobial resistance, factors such as behaviour and environment are the 
more implicated (Larson, 2007). Behavioural factors include improper use of antibiotics, such as 
prescription for nonbacterial infections and self-prescription of antimicrobials in the community 
(Chatterjee et al., 2016). Most of the time the contact with animals, contaminated products, 
crowding, impaired cleanliness of the skin, integrity and failure to vaccinate diseases also lead to 
antimicrobial resistance (WHO, 2010). The lack or poor sanitation in hospitals and in the 
community increases the rapid dissemination of resistant bacteria in vulnerable patients or in the 
community (Cars et al., 2008). Contaminated food by resistant bacteria and contaminated animals 
can easily spread antibiotic resistance to people and animals (Butaye et al., 2006). 
The improper use of traditional medicines or practices was described by WHO to have a  fatal 
effect  and that, further studies are needed to assess the safety and effectiveness " of different 
practices and plants used by traditional medicine systems (WHO, 2004). 
 
1.2.3.4 Treatment with traditional medicine 
Traditional medicine, commonly known as indigenous or folk medicine, includes medical aspects 
of traditional knowledge that developed in different cultures over years before the era of 
conventional medicine (WHO, 2004). The WHO (2004) defines traditional medicine as "the sum 
total of the knowledge, skills, and practices based on the theories, beliefs, and experiences 
indigenous to different cultures, whether explicable or not, used in the maintenance of health as 
well as in the prevention, diagnosis, improvement or treatment of physical and mental illness." 
Traditional medicines are relied by, up to 80% (WHO, 2002) of the population in some Asian and 
African countries for their primary health needs. It is often called alternative medicine when 
adopted outside of its traditional culture (WHO, 2004) and includes some practices known  as 
Ayurveda, Siddha medicine, Unani, ancient Iranian medicine, Islamic medicine, traditional 
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Chinese medicine, traditional Korean medicine, acupuncture, Muti, Ifa, and African traditional 
medicine (WHO, 2002).  
Traditional medicine (TM) includes a variety of health practices, knowledge, methods and 
philosophies containing plant, animal and mineral medicines, manual techniques, exercises and 
divine therapies for well - being and treatment, diagnosis or disease prevention (WHO, 2002).  
1.2.3.4.1 Benefit effect of using TM 
TM therapies can have less adverse effects than conventional therapies; they are generally 
available, affordable and widely used in developed countries (WHO, 2002). The advantages of 
TM are its diversity and flexibility, its availability and cost efficiency in many parts of the world, 
its widespread recognition in low- and middle - income countries, its relatively low cost and the 
relatively low level of technology. As a result, TM therapies can help to improve the healthcare 
system in several countries (WHO, 2002).  
Approximatively 27 million South Africans, including PLWA and infected bacteria, are estimated 
to rely on traditional medicine for their primary health needs (Street et al., 2008).  This is relative 
because of good plant accessibility, affordability, confidentiality of health information between 
patients and practitioners and the high cost of synthetic medicines medicinal plants are also 
believed to combat certain symptoms, including weight loss, skin disorders, energy shortages, 
lack of appetite, diarrhea, nausea and vomiting, treatment of side effects of ARVs as well as 
dizziness, fungal infections, pain and stomach upsets(Petzer and Mngqundaniso, 2008; Richter, 
2004). 
Scientific studies in many TM therapies have shown that the use of medicinal plants was effective 
in patients with HIV / AIDS and cancer (Carlsson et al., 2001; Power et al., 2002). Although some 
plant extracts like Psidium guajava, Artemisia afra and Erythrina lysistemon have not been 
scientifically investigated, traditional healers have used them to treat the growth of bacteria, 
viruses and other microbes (Mativandlela, 2007) and especially  to treat certain types of  wounds, 
abscesses, arthritis, diarrhea, and influenza (Van Wyk and Gericke, 2000).  
1.2.3.4.2 Risk of using TM 
Incorrect use of TM can lead to terrible outcomes. Traditional medicine therapies are usually used 
as self - care treatments. However, TM products are poorly regulated in many countries, so many 
of the risks to consumers concern the safety and quality of TM products (Mills et al., 2005; Moss, 
2001, Eisenberg et al., 1998).  
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For example, the Chinese herb ma huang (Ephedra sinica) containing ephedrine is used for 
respiratory problems and can cause heart attacks. (Ang-Lee et al., 2001); Kava can cause serious 
liver damage in the long term use (Stevinson et al., 2002); and ginkgo used to stimulate peripheral 
circulation may lead to bleeding during operation (Ang-Lee et al., 2001).  Interactions may pose 
a risk to patients who use TM at the same time with conventional medicines. Studies revealed that 
many patients used TM concurrently with conventional medicine, often without informing their 
health care provider; thus it is important to be aware of the possibility of interactions that may 
result from the concurrent use of several TM medication therapies and/or conventional medicines 
(Eisenberg et al., 1998; Yuan et al., 2016).  
 1.2.3.4.3 Treatment failure 
A standard definition of treatment failure does not exist, but measurements can be defined 
clinically, virologically and immunologically. Since the main expected effect of antimicrobial 
therapy is mainly to reduce viral load by viral suppression (antiretroviral) and manage infectious 
disease by killing or injuring bacteria (antibiotics). A treatment failure occurs when the infection 
cannot be controlled by an antiviral or antibiotic. Drug resistance, drug toxicity and poor 
adherence to antimicrobial treatment are the most contributing factors to treatment failure (Aldous 
and Haubrich, 2009). The decision to change the treatment pattern does not mean that the next 
one will be successful; however, it is correct to find out why the previous therapy has failed. Most 
of the time the response may reveal that the treatment was not taken on time or in the prescribed 
manner or that the treatment was completely stopped. Furthermore, It may also happen because 
of drug resistance or because of treatment that was not powerful enough or because the drug was 
poorly absorbed (Farup et al., 2011).  
For example, a study showed that the primary health care community in South Africa used 
Hypoxis hemerocallidea as an immunostimulant in HIV / AIDS patients (Albrecht et al., 1995). 
Nevertheless, A study done on the same plant showed that up to 86% of normal CYP 3A4 isoform 
activity was inhibited. P-glycoprotein showed moderate activity from exposure to hypoxis, with 
an activity strength of 42–51% compared to the known P-gp verapamil inhibitor. Hypoxis 
exposure resulted in almost 2-fold PXR activation (p < 0.05). After an in vitro study, the 
concentration used for experimentation was relatively high; hypoxis revealed a high potential to 
interact with enzymes that metabolize HIV drugs and subsequently could lead to treatment failure 
as well as drug resistance and drug toxicity (Mills et al., 2005). However the treatment failure due 
to the concurrent use of both TM and prescribed medicines is not yet properly highlighted.  
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1.3 Rationale of the study 
The indiscriminate use of antimicrobials has led to drug resistance and treatment failure of many 
bacterial strains; the emergency of microbial resistance becomes a medical disaster (Jia et al., 
2016, Martini and Eloff, 1998). The appearance of antimicrobial resistance has been directly 
linked to the use and overuse of antimicrobials and may therefore also be linked to poor 
knowledge of the use of traditional medicine at the same time with prescribed antibiotic and/or 
antiviral medicines. Traditional medicine can play a major role in cutting down the spread of 
microbial infection but also can contribute to its treatment failure (Martini and Eloff, 1998). 
The effects of various medicinal plants used simultaneously with prescribed medicine can 
therefore be improved, opposed and/or interacted. (Fugh-Berman, 2000; Kamatou et al., 2006). It 
is also known that the irrational use of antimicrobials can lead to the failure of treatment and the 
adaptation of micro - organisms to persist with antiviral and/or antibacterial medicines, while the 
synergistic effect of antibiotic and plant extracts against resistant pathogens confronts problems 
of toxicity and overdose (Goff et al., 2017, Nascimento et al., 2000, Russel, 1998).  
M (2009) showed that the prevalence of concurrent use of TM and standard medicines in Nsukka, 
Nigeria was high, out of 278 surveyed patients,193 patients (69.4%) were at high risk due to 
population demographic and socio - economic characteristics (MO, 2009). Kadhim et al. (2015) 
also conducted a similar study in Iraq, showing that the consumption of TM with prescribed 
medicines by Iraqi patients was quite high. In a total of 367 patients, 73.6% consumed 21 types 
of TM (crude or refined) either alone or in combination with conventional medicine.  
Furthermore, in two healthcare facilities in southwestern Nigeria, Chukwuemeka et al. (2017) 
found that 42.7% of HIV outpatients in a total of 351 recruited HIV - positive patients used herbal 
medicines simultaneously with ARVs, then it was statistically significant upon cross-tabulation. 
The HIV treatment was improved but also the interaction between TM and standard medicine was 
potentially life threatening. In South Africa, Sibanda et al. (2016) reported that the prevalence of 
concurrent use of ARV and TM by PLWA was quite low, such as 4, 98% in a total of 281(14/281) 
compared to, 65 % (185/281) of participants who used TM and ART before diagnosis of HIV.  
However, the need of further study is important, because the limited knowledge of interactions in 
the treatment of viral and bacterial infections through concurrent use of TM and conventional 
medicines remains from both, THPs and BHPs. 
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1.4 Research Questions, Aim and Objectives 
1.4.1 Research questions 
The general question that this study aimed to answer was as follows: “Is there any antimicrobial 
resistance and or treatment failure among patients attending out-patient departments (OPD) in 
selected healthcare facilities namely Stanger Hospital and Umphumulo Hospital and who use     
concurrently traditional medicine, antibiotics and antiviral medicines?”  
The specific questions of this study were as follows: 
1. What is the prevalence of Sexually Transmitted Diseases and Respiratory infections (with 
emphasis on Tuberculosis) in patients/clients seen by THPs for antibacterial and antiviral 
treatments around healthcare facilities in Ilembe district? 
 2.  Do patients attending out –patient departments in healthcare facilities use concurrently TM, 
prescribed ATB and ARVs for viral and bacterial infections? 
3. How do THPs and biomedically trained healthcare professionals perceive interactions between 
TM and prescribed ATB and ARVs for viral and bacterial infections? 
4. What types of TM are used by THPs to treat viral and bacterial infections in their practices? 
5. What types of prescribed ATB and ARVs are used by those patients who combined both 
prescribed medicines and TM?  
6. What are the types of interactions found including treatment failure and AMR among those 
patients who use prescribed ATB, ARVs and TM?  
1.4.2 Aim  
This study aimed to determine whether any antimicrobial resistance and treatment failure occur 
among patients attending out-patient departments in selected healthcare facilities and who use 
concurrently traditional medicine, antibiotics and antiviral medicines in ILembe district, 
KwaZulu- Natal. 
1.4.3 Hypothesis 
Indiscriminate use of traditional medicine in conjunction with prescribed antimicrobials 
can lead to treatment failure and antimicrobial resistance. 
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1.4.4 Objectives 
The specific objectives of this study were as follows: 
1. To determine the prevalence of Sexually Transmitted Diseases and Respiratory infections (with 
emphasis on Tuberculosis) in patients/clients seen by THPs for antibacterial and antiviral 
treatments around healthcare facilities in Ilembe district.  
2. To assess whether patients attending out –patient departments in healthcare facilities use 
concurrently TM, prescribed ATB and ARVs for viral and bacterial infections. 
3. To explore the way THPs and biomedically trained healthcare professionals perceive 
interactions between TM and standard prescribed ATB and ARVs for viral and bacterial 
infections. 
4. To determine types of TM used by THPs to treat viral and bacterial infections in their practices. 
5. To evaluate types of prescribed ATB and ARVs are used by those patients who combined both 
prescribed medicines and TM.  
6. To explore the types of interactions found including treatment failure and AMR among those 
patients who use prescribed ATB, ARVs and TM. 
 
1.5 General Methodology 
1.5 1 Study design 
This study was a cross –sectional descriptive study, based on an exploratory mixed- method 
approach. The study was carried out in two phases as follows:   
Phase 1 
This was a survey based on a qualitative descriptive study with four parts in using purposive 
sampling method described by Patton (2002): 
- Phase 1.A, Survey among THPs.  
- Phase 1.B, Survey among patients seen by the same THPs approached in phase 1A.  
- Phase 1.C, Survey among BHPs consisted of doctors and professional nurses. 
- Phase 1.D, Survey among outpatients seen by both THPs and BHPs  
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Phase 2 
This phase consisted of a quantitative analytical study, using a medical chart review among 
outpatients seen by both THPs and BHPs described in phase 1C.  
1.5.2 Study area 
This study was conducted in the ILembe District located in KwaDukuza on the East coast of the 
province, bordering the Indian Ocean and comprises four municipalities: Mandeni, Ndwedwe, 
KwaDukuza, and Maphumulo. The district covers 3 269 km2, the smallest provincial district in 
KwaZulu-Natal, with a population size of 630 464 people and it is approximately 75 km from 
Durban with a population including 90.8% of black African, 2.4% of the white population and 
6.8% of others. The majority of the population in the district consists of native isiZulu speakers 
(82%) followed by native English speakers (9.6%), native Xhosa speakers (3.3%) and others 
(5.5%) (KZNHealth, 2017). The district comprises four local municipalities located between 
Durban and Richards Bay: Mandeni, KwaDukuza, Maphumulo, and Ndwedwe with a small urban 
area in which the majority of the area is rural. The district’s rural and traditional areas are 
characterized by low educational levels, high unemployment rates, and a severe lack of basic 
services (KZNHealth, 2017). 
ILembe Health District has four hospitals: Montebello District hospital, Stanger Provincial 
hospital, Umphumulo District hospital, and Untunjambili District hospital. This study included 
two Hospitals, Stanger Provincial hospital, and Umphumulo District hospital. Both hospitals 
belong to the ILembe health department in the public sector. 
 
Fig. 1.1: Map of study area (http://www.kznhealth.gov.za/ilembe.htm).  
 
Ilembe district  
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1.5.3 Study population, inclusion and exclusion criteria and Sample size 
1.5.3.1 Study population 
The population of this study comprised participant such as THPs and their patients, BHPs 
consisting of doctors and professional nurses and finally out-patients attending public healthcare 
facilities in Ilembe district, KwaZulu-Natal province.   
1.5.3.2 Inclusion and exclusion criteria 
This study involved THPs and BHPs as well as patients seen by them, aged 18 years old and 
above. BHPs who have had treated bacterial and viral infections in the past three months as well 
as outpatients referred by them were included in this study. Other outpatients attending the 
outpatient department (OPD) of the two healthcare facilities were as well included in this study. 
THPs, BHPs and patients less than 18 years old were excluded in this study. BHPs who have had 
not treated bacterial or viral infections in the last three months were excluded in this study. 
1.5.4 Recruitment and selection of participants 
Participants were recruited according to our inclusion and exclusion criteria pertinent to the study 
research questions. A researcher had to find a sample that matched his established criteria. 
Phase 1 
 Phase 1A (THPs): THPs were recruited purposively using snow ball technique. 
They were approached at their workplace during their business hours.  Community head and 
leaders of traditional organizations were approached to assist with the identification of 
traditional healers operating in the ILembe district. 
 Phase 1B (Patients seen by THPs): after interviews with THPs, with their permission 
(consent), we had to speak to the patients seen by them. Snowball sampling technique was 
used as well. After our conversation with patients seen by THPs, they were asked whether they 
had used at the same time traditional and conventional medicine; to those that the answer was 
“yes”, they were asked if they could indicate which healthcare facility they have attended to 
in ILembe district. 
 Phase 1C (BHPs): they were mostly recruited during their lunch time at the Hospitals besides 
those recruited according to the indications got from their patients treated as well by THPs.  
 Phase1D: patients seen by both THPs and BHPs as identified in phase 1B were recruited and 
selected during clinic business operating hours. The intention to include this category of 
patients was to allow having access to their medical charts. 
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Phase 2 
This second phase implicated a medical chart review of patients seen by both THPs and BHPs at 
the Hospitals identified in phase 1B. 
1.5.5 Sample size and sampling technique 
Phase 1 
This phase was a qualitative descriptive study, based on the principle of saturation. The sample 
size calculation is based on the assumption that in a qualitative study the principle of saturation 
is often used whereby a researcher cannot gather new information after a maximum of 50 
participants (Fusch and Ness, 2015, Hennink et al., 2017, Saunders et al., 2018).  
 Phase 1A 
The sampling method was the purposive sampling using snow ball technique for identifying 
THPs, a maximum of fifty participants was required. 
 Phase 1B 
After seeing THPs in phase 1A, through snowball technique, patients seen by them were recruited. 
The calculation for sample size for patients was based on the “principle of saturation” of the 
Ilembe population which utilized simultaneously both Traditional medicine and prescribed 
medicines.   A minimum of fifty participants was interviewed. 
Phase 1C 
A minimum of fifty of BHPs was included in this phase, using a purposive sampling. This 
minimum sample size was equally divided into the two hospitals (Stanger Provincial hospital and 
Umphumulo District hospital) included in the study. 
 Phase 1D 
A minimum of fifty of outpatients was included in this phase, using a purposive sampling. This 
minimum sample size was equally divided into the two hospitals (Stanger Provincial hospital and 
Umphumulo District hospital) 
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Phase 2 
This phase was a quantitative descriptive study, including a minimum of 400 outpatients’ medical 
records. The calculation for sample size for patients was based on the assumption of the normal 
distribution; 50% as an equal distribution with 95% of confidence interval, 5% of margin error of 
the Ilembe population which used simultaneously both Traditional medicine and prescribed 
medicines.   
1.5.6 Data collection techniques and Tools  
The data collection method adopted in this study was as follows: 
Phase 1: This phase consisted of researcher administered interviews.  
This phase was an explorative study with semi-structured interviews with 132 informants (THPs, 
Patients seen by THPs, BHPs and patients seen either by BHPs alone or by both THPs and BHPs) 
was conducted on January 2018.  A total of 17 THPs and 15 patients seen by them were initially 
identified and interviewed by snowball sampling technique; while 100 participants including 50 
BHPs and 50 outpatients attending the two selected healthcare facilities. An interview face to face 
was used and the questionnaire form used for data collection was specifically developed for the 
study in which were included in section A the participants’ address, age, gender, marital status, 
educational level, language spoken, occupation as well as in section B, information relating to the 
use of TM and their related conditions and in section C, information on any clinical outcomes 
including treatment failure and antimicrobial drug resistance from the concomitant use of TM and 
prescribed medicines. 
Data collection had four (4) phases. The first phase was done with THPs which were recruited 
purposively using snowball technique. Some of them were approached at their workplace during 
their business hours and other at their households and the only tool used was an interview 
questionnaire (Appendix 8). Phase two was done with patients seen by THPs using snowball 
technique with their permission (see Appendix 9 and 12); they were asked whether they had used 
at the same time traditional and conventional medicine; to those that the answer was “yes”, they 
were asked if they could indicate which healthcare facility they had attended in ILembe district. 
The third phase of the interview was with BHPs (Appendix 6), they were recruited at the hospitals. 
BHPs were recruited purposively in the two selected healthcare facilities during their business 
operating hours. Finally, the fourth phase was conducted among outpatient, only those who were 
consulted by both THPs and BHPs and those who were attending the outpatient department 
(Appendix 7). 
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From phase 1.A to phase1.D, a researcher administered interview using a questionnaire. Data was 
collected 4 days per week during seven weeks as data collection period. The questionnaire was 
translated from the English into IsiZulu by an expert for content validity.  
Phase 2: This second phase was a medical chart review. 
Medical chart records of adult patients, aged 18 years and above, irrespective of gender were 
selected at the OPD of the two selected healthcare facilities as well as at their respective 
tuberculosis (TB) and HIV clinics during clinic visit hours. Patients’ medical records from 
January 2017 to January 2018 were assessed and selected according to the study’s inclusion and 
exclusion criteria during the data collection period between February and March 2018. Records 
of patients who used concurrently TM and prescribed antimicrobials as well as who developed 
any side effects and/or interactions were reviewed in details.  
 
1.6 Layout of the dissertation/ structure of the dissertation 
The dissertation is entitled: “Concurrent use of traditional medicine and prescribed antibiotics 
and/or antiviral medicines and their effects on antimicrobial resistance and treatment failure in 
Ilembe district, Kwazulu-Natal province,  South Africa.  
This study using a mixed method approach has been conducted in the community and in two 
different healthcare facilities namely Stanger hospital and Umphumulo hospital in the Ilembe 
district, KwaZulu-Natal province, South Africa. 
The dissertation consists of : 
 Chapter 1: Provides a background and a brief overview of literature of the proposed study. 
This chapter highlights an overview of the rationale of the study, research questions, the aim, 
and objectives of the study. A general methodology has been included to achieve aim and 
different objectives of the study. 
 Chapter 2: Consists of a systematic review protocol submitted to Bio Med Central, Systematic 
review journal under the title “Mapping evidence of collaboration between traditional health 
practitioners and biomedically trained healthcare professionals in the reduction of 
antimicrobial resistance in sub-Saharan Africa: A systematic review protocol”  
 Chapter 3: Provides an original manuscript article submitted to the African Journal of 
Biomedical Research, under the title “Perspectives on the concurrent use of traditional and 
prescribed antimicrobial medicines for infectious diseases: a triangulation study involving 
biomedically trained healthcare professionals, outpatients, traditional health practitioners and 
their patients. 
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 Chapter 4: Comprises an original manuscript article submitted to the journal BMC, 
Complementary and Alternative medicine under the title “Evaluation of concomitant use of 
prescribed antiviral, antibacterial and/or antifungal medicines with traditional medicine in 
Ilembe district, South Africa: A medical chart review” 
 Chapter 5: Provides the Synthesis which includes general conclusions, strengths and 
limitations of the study then recommendations.  
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ABSTRACT 
Background  
The overuse of prescribed antimicrobials, concurrent use of both traditional medicine and 
prescribed antimicrobials has been shown to lead to antimicrobial resistance. The absence 
of collaboration between traditional health practitioners and biomedically trained 
healthcare professionals can contribute to antimicrobial resistance, treatment failure, 
overdose, toxicity and misadministration. This scoping review explores evidence on 
collaboration between traditional health practitioners and biomedically trained healthcare 
professionals in the reduction of antimicrobial resistance and treatment failure in bacterial 
and viral diseases.  
Methods/design  
We will search electronic databases such as Science Direct, Google scholar, PubMed, 
MEDLINE via EBSCOhost. We will also search reference lists of included studies. A 
two-stage mapping procedure will be carried out. Stage one (1) will consist of title, 
abstracts and full article screening, respectively. A piloted screening form guided by the 
defined eligibility criteria will be used. Stage two (2), data will be extracted from the 
included studies. Parallel screening and data extraction will be conducted by two 
reviewers. Mixed methods appraisal tool (MMAT) will be used to assess the quality of 
the included studies. NVIVO version 11 will be employed to aid pertinent thematic 
analysis. The outcomes of interest will be as follows: Primary outcome will be the 
prevention and the reduction of antimicrobial resistance. Secondary outcomes: Effective 
collaboration between traditional healthcare practitioners and biomedically healthcare 
professionals.  
Discussion 
This review anticipates uncovering pertinent publications reporting the evidence of 
collaboration between traditional health practitioners and biomedically trained healthcare 
professionals in the reduction of antimicrobial resistance in sub-Saharan Africa. The sum 
up of evidence acquired from the included studies will help guide for future research. The 
result from the research will be print and electronically exposed.  
Systematic review registration: PROSPERO CRD42017072952  
Keywords: Traditional Health Practitioners - Collaboration - Absence - Prevention - 
Effective - sub-Sahara Africa.  
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Background 
Traditional treatment or  indigenous health system cannot considered to be of a lower  
quality than the mainstream  healthcare system, in contrast it is thought to be desirable 
and needful  in treating a range of several  health troubles or difficulties that mainstream  
healthcare system fails to cure sufficiently [1, 2]. In the view of Qi and Kelley [2], 
traditional herbal mixtures are a reliable, believable and dignified source of health care. 
Bacterial and viral infections are currently common; some pathogens have become 
resistant to multiple classes of antimicrobials [3]. Microbial adaptation allows microbes 
to persist despite the presence of an antibiotic or antiviral agent; this reduces the potential 
human health benefit derived from antibiotics and/or antiviral medicines [4, 5].  
The ratio of traditional health practitioners and biomedically trained professionals to the 
general population in the sub-Saharan of Africa is approximately 1:500 and 1:40000, 
respectively [6]. In addition to their modern biomedical treatment, up to 70 percent of 
South Africans are usually consulted by an estimated 200 000 indigenous traditional 
healers [6, 7]. Approximatively 27 million South Africans, including people living with 
HIV/AIDS and bacteria infected people depend on traditional medicine (TM), for their 
primary health care needs [8]. STIs such as Tshofela/drop (gonorrhea), Thosola (syphilis), 
some other specific bacterial infections and assumed HIV/AIDS are the most common 
treated conditions and problems by THPs [9]. This is probably due to good accessibility 
of plants, affordability, confidentiality of health information between the patient and 
practitioner and the high cost of synthetic medicines [10]. Furthermore, consumers 
believe that certain infections such as acne, warts, shingles and STIs cannot be treated 
with western medicine by BHPs but rather by THPs [11, 12]. Medicinal plants are 
effective, cheap, readily available and used for cultural reasons. 
 In South Africa, antimicrobial resistance (AMR) is extremely prevalent, some bacteria 
and/or viruses are becoming so resistant that there is either only antimicrobial of last 
resort or infections are untreatable [13]. AMR in South Africa is driven by many factors 
such as the careless use of   prescribed antimicrobials,  the use of traditional medicine 
(TM) currently not regulated, the lack of collaboration between traditional health 
practitioners (THPs) and biomedically trained healthcare professionals (BHPs), with the 
result of treatment failure, misadministration, interactions and  toxicity [14]. With a view 
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to conceptualizing the conditions for collaboration between the two systems, Pretorius  
[15] proposed the analogical model of the Biomedical/Traditional Medical Relationship, 
this model shows clearly that each aspect of the traditional medicine system may be linked 
to the western medicine system such as mutual referral. In addition, the WHO have 
adopted strategies to ensure the integration of collaboration between research institutions 
and THPs based on research and management of patients; and between THPs and BHPs 
in human immuno deficiency virus and acquired immune deficiency syndrome (HIV/ 
AIDS) prevention and sexually transmitted infections (STIs)/tuberculosis programs [16]. 
Although the use of TM has increased, not currently regulated, with the result of 
enhancement of the activities of standard medicines when used concurrently with TM 
[17].  Nascimento et al., reported that the danger of misadministration, drug interactions, 
overdose, toxicity, especially the problem of drug resistance and treatment failure can 
occur when TM and prescribed antimicrobials are simultaneously and indiscriminately 
used [18]. This review aims to map the evidence on the collaboration between THPs and 
BHPs in the reduction of antimicrobial resistance in sub-Saharan Africa. 
Methodology 
 Scoping review 
A scoping review of peer-reviewed literature will be conducted on the following specific 
points: concurrent use of traditional medicines and prescribed antimicrobials, 
collaboration between THPs and BHPs and treatment of bacterial and viral diseases. 
Selection of scoping review method was to make easy the mapping of  the topic under 
study and to build evidence around the related subject [19]. This  review will  use the 
framework developed by Arksey and O’Malley [20]. This framework stipulated the 
following steps (a) identification of   research questions, (b) identification of pertinent 
studies, (c) charting the data, and (d) collation, summary and report of findings. 
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Identifying the research questions, aim and objectives 
The general research question of this study is “What is the evidence of collaboration 
between THPs and BHPs in the reduction of antimicrobial resistance in bacterial and viral 
diseases?” The specific research questions to answer the general question are as follows: 
1. What is the prevalence of patients/clients seen by THPs for antibacterial and 
antiviral treatments? 
2. What is the evidence of the concurrent use of TM, prescribed ATB and ARVs 
medicine for viral and bacterial infections? 
3. What is the evidence of the perceptions of TPHs and BHPs about interaction 
between TM and prescribed ATB and ARV medicine for viral and bacterial 
infections? 
4. Is there a bidirectional referral of patients between THPs and BHPs in the 
management of bacterial and viral diseases? 
Aim 
To map the evidence of collaboration between THPs and BHPs in the reduction of 
antimicrobial resistance and treatment failure in bacterial and viral diseases.  
          Objectives 
1. To assess the prevalence of patients/clients seen by THPs for antibacterial and 
antiviral treatments. 
2. To determine the evidence of the concurrent use of TM, prescribed ATB and 
ARVs medicine for viral and bacterial infections. 
3. To map the evidence of the perceptions of TPHs and BHPs about interaction 
between TM and prescribed ATB and ARV medicine for viral and bacterial 
infections. 
4. To determine whether there is any bidirectional referral of patients between THPs 
and BHPs in the management of bacterial and viral diseases. 
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Eligibility criteria for research questions  
The study will use an amended Population, Intervention, Comparison, Outcomes and 
Study setting (PICOS) framework to evaluate the eligibility of research questions (Table 
1). 
Table 2. 1 PICOS framework for determination of eligibility of review question 
Criteria Determinants 
Population THPs and BHPs. 
Intervention Collaboration between traditional and 
biomedically healthcare workers. 
Comparison Absence of collaboration between THPs 
and BHPs. 
Outcomes Primary outcome: Prevention and 
reduction  of antimicrobial resistance 
Secondary outcomes: Effective 
collaboration. 
Setting Sub-Sahara Africa. 
 
Identification of pertinent studies  
 Studies that utilize mixed methods, qualitative and quantitative published in peer-
reviewed journals and grey literature, from January 2005 to May 2018, addressing the 
above research questions will be included. Different types of study designs will be used 
during the process of screening data.  Electronic search will be conducted from the 
following electronic databases: Science Direct; Google Scholar PubMed and; MEDLINE 
via EBSCOhost. Internet sites such as the World Health Organization (WHO) and 
government internet sites will be explored for reports and policies on collaboration of 
healthcare workers, measures on antimicrobial resistance, safe use of traditional 
medicine, concurrent use of both traditional medicine and prescribed medicines. Through 
“Cited by”, other articles will also be searched in the reference lists of selected articles. 
The keywords for the search will include Traditional Health Practitioners, collaboration, 
absence, prevention, effective and sub-Sahara Africa.  
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Study selection  
To be  certain that the included studies have the specific information according to the 
eligibility criteria, they should respond to the questions on the evidence of collaboration 
between THPs and BHPs in the reduction of antimicrobial resistance and treatment failure 
in bacterial and viral diseases. 
Eligibility criteria 
 Inclusion criteria 
 For the inclusion of publications in this study, they should match with the 
undermentioned criteria: 
 There will be a language restriction (English and French) on the inclusion of 
studies.  
 Focus on strategies of collaboration between THPs and BHPs. 
 Publications from January 2005 to May 2018. 
 Report on cases of treatment failure, drug-interactions, drug-resistance and 
antimicrobial stewardship.  
 Publications on the use of traditional medicine in conjunction with prescribed 
antimicrobials by community members of 18 years and above.  
 Reports on death causes worldwide, with special emphasis on sub-Saharan 
Africa.  
Exclusion criteria 
 Studies will be excluded if they meet the following characteristics: 
 Articles published before 2005 and after May 2018. 
 Articles that they do not report on the use of TM for the management of bacterial 
and viral diseases.  
 Articles that report on other diseases than infectious diseases. 
A pilot study will be carried out to check the appropriateness of the chosen studies, 
keywords and databases. Selected articles will be shared between two reviewers using 
research manager software such as Endnote library or Mendeley. A comprehensive title 
screening according to the eligibility criteria will be conducted by both first and second 
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reviewer. Eligible publications will be exported using either Endnote management 
software or Mendeley library. Articles will be checked for duplication using   EndNote 
program or Mendeley. 
Table (2) below presents how publications will be recorded. Full articles and abstracts of 
studies will be screened according to the eligible criteria. A third reviewer of the study 
will be considered in case of non-accordance between the two previous reviewers. In case 
of difficulty to find some articles, the assistance of the UKZN library will be needed. 
However, for authors whose publications will be cited and difficult to retrieve, they will 
be asked for assistance through a correspondence letter. If they do not respond to the 
correspondence, then their articles will be excluded.  
Table 2. 2 Electronic search record 
Keyword search: Search engine used Number of articles or publications selected 
Mainstream  healthcare system  
Traditional herbal mixtures  
Microbial adaptation 
Mutual referral  
Concurrent use   
Bacterial  
Viral 
HIV/AIDS 
Infectious diseases  
Collaboration 
 
Fig.2.1 illustrates a PRISMA chart used for the selection of study strategies. The undermentioned 
procedure will be followed: 
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Fig. 2.1 Study selection procedure. 
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Charting the data 
Table (3) presents the flow or the charting of included studies. A data charting form will be 
conceived and piloted. Variables to include in order to summarize the included articles are shown 
in Table 3.  
Table 2.3 Form for Data charting  
Author and date 
Article or study title 
Journal full reference  
Aims or  main research question  
Characteristics of participants 
Recruitment context (e.g. where participants were 
recruited) 
Sampling method  
Study method or design  
Theoretical background  
Data collection (what data collection methods were used?)  
Data analysis (how was the data analyzed?)  
Intervention  
Intervention outcome  
Most relevant findings 
Conclusions  
Comments 
 
 
Summarizing, collation and reporting of findings 
This study aims at mapping the evidence of collaboration between THPs and BHPs in the 
reduction of antimicrobial resistance and treatment failure in bacterial and viral diseases 
in sub-Saharan Africa and to summarize the results as found from the included studies. 
Following data extraction, thematic content analysis will be carried out to code the data 
according to the following themes:  types of interactions registered in publications; causes 
of treatment failure, approach system and medicinal plants used by THPs to treat 
infectious diseases; barriers and facilitators towards collaboration between THPs and 
BHPs and; types of infectious disease not cured by western medicine. Emerging theme 
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will also be coded. NVIVO software version 11 will be employed to assist with coding 
of the themes [21].  
 Coding data from the included articles  
 Categorizing the codes into major themes  
 Displaying the data  
 Identification of  key patterns in the data and identification of subthemes 
 Summarizing 
Synthesis  
Resulting themes will be analyzed and critically examined in relationship with the 
research questions. The meanings of the results in reference to the aim of the research and 
the implications of these results for the forthcoming research, practice and policy will be 
analyzed by reviewers.   
Quality appraisal  
 The mixed method appraisal tool (MMAT)-Version 2011 will be used to evaluate the 
quality of the included studies [22]. We will assess   the appropriateness of the aim of the 
study, adequacy and methodology, study design, participant recruitment, data collection, 
data analysis, presentation of findings, authors’ discussions and conclusions.  
Discussion  
This scoping review will be carried out as a first part of a larger study on the evidence of 
collaboration between THPs and BHPs in the reduction of antimicrobial resistance and 
treatment failure in bacterial and viral diseases in sub-Saharan Africa.  This review will 
identify types of interactions registered in publications, causes of treatment failure, 
approach system and medicinal plants used by THPs to treat infectious diseases, barriers 
and facilitators towards collaboration between THPs and BHPs, types of infectious 
disease not cured by western medicine. Although there is a growing acknowledgement 
that healthcare systems are encouraging ways of collaboration between THPs and BHPs 
[23-26], but the paucity of knowledge about collaboration between THPs and BHPs still 
with regard to antimicrobial resistance, treatment failure or other interactions. In addition, 
the existence of challenges related to the availability of relevant full text articles.  
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Articles that report on other diseases than infectious diseases will be excluded because 
this study is focused on the use of prescribed antimicrobials and TM in the treatment of 
infectious diseases. This review excludes all studies that do not report on the use of TM 
for the management of bacterial and viral diseases. All the reports on deaths that are not 
caused by infectious diseases and those are not reporting cases of interaction either in TM 
alone, prescribed antimicrobials alone or in the concurrent use of both TM and prescribed 
antimicrobials will be excluded. 
Results from this study will be of benefit to researchers by highlighting gaps in evidence 
that may need further investigation. Study findings will be disseminated by peer reviewed 
publications. 
Abbreviations 
THP: traditional healer practitioners BHP: biomedically healthcare professionals 
PICOS: population, intervention, comparison, outcomes and study setting. MMAT: 
Mixed Methods Appraisal Tool HIV/AIDS: Human Immunodeficiency Virus/ Acquis 
immunodeficiency deficiency Syndrome. TM: Traditional Medicine. 
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In order to evaluate perceptions about the concurrent use of prescribed antimicrobial and 
traditional medicines, four (4) types of participants namely traditional healer practitioners, 
patients seen by them, biomedically healthcare professionals and outpatients have been 
interviewed on the concurrent use of traditional and prescribed medicines for infectious 
diseases  and their effect on antimicrobial resistance and treatment failure. This chapter is 
presented in a manuscript format, it has been prepared and submitted following the authors 
guidelines of the journal African Journal of Biomedical Research (AJBR). This manuscript 
is under review. 
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ABSTRACT 
Background: Traditional medicines are generally available, affordable and commonly 
used as self-care treatments. However, their incorrect use lead to fatal outcomes. 
Individuals may consult both traditional healer practitioners (THPs) and biomedically 
trained healthcare professionals (BHPs) for their infections. This study aimed at 
determining whether any antimicrobial resistance and treatment failure could occur 
among patients, attending outpatient departments of selected healthcare facilities, who 
used concurrently prescribed antimicrobial and traditional medicines. 
Methods: A survey was conducted using a questionnaire to assess the perceptions of 
respondents on the concurrent use of traditional and prescribed medicines for infections. 
One hundred and thirty two respondents were included namely THPs, patients seen by 
them, BHPs and outpatients. 
Results: A small number of medicinal plants were used in the treatment of infections and 
65.62% of THPs and their patients (21/32) mixed different herbs for the treatment of 
infections. Respondents agreed that the combination of traditional and prescribed 
medicines for infections may lead to interactions, adverse effects; infectious diseases may 
get worse if the time lapses between the two medicines is not used. However, BHPs and 
outpatients reported that combining traditional with prescribed medicines for infectious 
diseases may result in drug resistance, especially resistance to antibiotics and they 
highlighted that the majority of patients came to the clinic with several complications 
such as kidney failure, vomiting, diarrhea and jaundice. 
Conclusions: The concurrent use of conventional and traditional herbal medicines may 
interfere or result in damaging some organs, failure of therapeutic effects and 
modification of pharmacological actions of administered medicines.  
KEYWORDS: Concurrent, traditional medicine, infectious diseases, prescribed 
medicines, interactions. 
 
 
 
 
 
 
 
 
 
  
37 
 
Introduction 
Treatment with traditional medicine 
Traditional medicine (TM), commonly referred to as indigenous or folk medicine, 
comprises medical and traditional knowledge formulated in several communities over 
generations prior to the modern medicine era (WHO, 2004). The World Health 
Organization (WHO) describes traditional medicine as " the sum of knowledge, abilities, 
and practices based on indigenous concepts, philosophies, and experiences of various 
cultures, whether explained or not, it is used to maintain well-being, prevent and treat, 
diagnose, improve physical and mental illness"(WHO, 2000). Traditional medicines 
include different practices, commonly known as herbal Ayurveda, traditional African 
medicine, Siddha medicine, Unani, Muti, Ifa, ancient Iranian medicine, acupuncture, 
traditional Chinese medicine in Islamic medicine and traditional Korean medicine (WHO, 
2002). 
Many people around the world choose traditional medicines or herbal products as a 
curative agent, either alone or in combination with others, to maintain their health. In 
some Asian and African countries, up to 80% (WHO, 2002) of the population depends 
on traditional medicine for their primary medical needs. In different traditional medical 
systems, plants are always the main source of medicines or treatment strategy. Some 
traditional Chinese medicine, such as Coumarin, Aescin, and Liu-jun-zi-tang, is used to 
improve postoperative side effects such as tiredness, pain, appetite, diarrhea, nausea, 
vomiting, and lymphedema at certain stages of cancer lesions (Qi et al., 2015). 
 
 Benefit effect of using TM 
TM treatments are frequently used in developed and developing countries where they are 
generally available and sustainable. TM treatments can have less adverse effects than 
conventional therapies (WHO, 2002). The benefits of TM include its diversity and 
flexibility, its availability and cost-effectiveness in many parts of the world; it is widely 
accepted in low- and middle - income countries and the relatively low level of 
technological input required. As a result, TM therapies can significantly contribute to the 
improvement of the healthcare system in many countries (WHO, 2002). 
Approximatively 27 million South Africans, including PLWA and infected bacteria, are 
estimated to rely on traditional medicine for their primary health needs(Street et al., 
2008). This is relative because of good plant accessibility, affordability, confidentiality 
of health information between patients and practitioners and the high cost of synthetic 
medicines (Ballabh et al., 2008); medicinal plants are also believed to combat certain 
symptoms, including weight loss, skin disorders, energy shortages, lack of appetite, 
diarrhea, nausea and vomiting, treatment of side effects of antiretroviral medicines 
(ARVs) as well as dizziness, fungal infections, pain and stomach upsets (Richter, 2004, 
Petzer and Mngqundaniso, 2008). 
Scientific studies in many TM therapies have shown that the use of medicinal plants is 
effective in patients with HIV / AIDS and cancer (Power et al., 2002, Carlsson et al., 
2001). Although some plant extracts like Psidium guajava, Artemisia afra and Erythrina 
lysistemon have not been scientifically investigated, traditional healers have used them to 
treat the growth of bacteria, viruses and other microbes (Mativandlela, 2007) and 
especially to treat certain types of wounds, abscesses, arthritis, diarrhea, and influenza 
(Van Wyk and Gericke, 2000). The use of Jiangzhi in association with atorvastatin 
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showed a synergistic effect in the improvement of lipid level of the blood without serious 
adverse effects (Wang et al., 2012). 
 Risk of using TM 
 
Traditional medical therapies are usually used as self-care therapies, and their improper 
use can lead to serious outcomes. TM products are, however, poorly regulated in many 
countries, and many of the risks to consumers concern their safety and quality products 
(Mills et al., 2005; Moss, 2001; Eisenberg et al., 1998). The combination of certain 
Chinese herbal preparations commonly used in cardiovascular diseases showed different 
interactions with cytochrome CYP450, either an induction effect with Ginkgo Tablet or 
an inhibition effect with compound danshen Tablet. In addition, a narrow therapeutic 
window and the accumulation of medicines in the body when using herbal medicines can 
lead to an increase of medicine concentration in the blood that leads to serious adverse 
effects as a consequence (Wang, 2015). The Chinese herb ma huang (Ephedra sinica), 
for example, which contains ephedrine, can lead to heart attacks as respiratory problems; 
as well as long-term use of kava (Piper methysticum) can lead to fatal liver injury and 
ginkgo (Gingko biloba) used to boost peripheral circulation may lead to bleeding during 
surgery (Ang-Lee et al., 2001). Interactions can be a risk for patients using TM with 
conventional medicines at the same time. Studies have shown that many patients use TM 
at the same time as conventional medicine, often without informing their health care 
provider; thus it is important to be aware of the possibility of interactions that may result 
from the concurrent use of several TM medication therapies and/or conventional 
medicines (Eisenberg et al., 1998). 
TM is commonly used in combination with conventional medicines, with most 
satisfactory results, but in some cases, the effect of the two treatments may be magnified, 
interacted and/or opposed (Fugh-Berman, 2000, Ramadan, 2017). Studies have shown 
that many patients used TM in conjunction with conventional medicine and therefore 
interactions could pose a risk at any stage of absorption, distribution, and elimination of 
pharmaceutical disposal, which could affect the pharmacokinetics of the medicine in the 
body (Müller and Kanfer, 2011, Di Minno et al., 2017). Medicinal plants such as 
Taraxacum officinale, Echinacea purpurea, Hypoxis hemerocallidea, Moringa oleifera 
and Lessertia frutescens induce the inhibition of cytochrome CYP450 enzymes that can 
alter antibacterial metabolism (ATB) or (ARV)s which lead to lack of efficacy and 
adverse effects experienced by  PLWA and using simultaneously TM  with ARVs (Müller 
and Kanfer, 2011, Mills et al., 2005). Individuals may consult both Traditional Healer 
practitioners (THPs) and biomedically trained healthcare professionals for bacterial and 
viral infections.  
However, there is a limited knowledge of interactions about the concurrent use of TM 
and prescribed medicines for bacterial and viral infections. This study aimed at 
determining whether any antimicrobial resistance and treatment failure could occur 
among patients, attending outpatient departments of selected healthcare facilities, who 
used concurrently prescribed antimicrobial medicines and traditional medicine in the 
Ilembe district, South Africa. 
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Methods  
 
Setting and design 
This study was conducted in the ILembe District. It is located in KwaDukuza on the east 
coast of the province, bordering the Indian Ocean and comprises four municipalities: 
Mandeni, Ndwedwe, KwaDukuza, and Maphumulo. The district covers 3 269 km2, the 
smallest provincial district in KwaZulu-Natal, with a population size of 630 464 people 
and it is approximately 75 km from Durban with a population including 90.8% of black 
African, 2.4% of the white population and 6.8% of others. The majority of the population 
in the district consists of native isiZulu speakers (82%) followed by native English 
speakers (9.6%), native Xhosa speakers (3.3%) and others (5.5%) (KZNHealth, 2017). 
The district comprises four local municipalities located between Durban and Richards 
Bay: Mandeni, KwaDukuza, Maphumulo, and Ndwedwe with a small urban area in which 
the majority of the area is rural. The district’s rural and traditional areas are characterized 
by low educational levels, high unemployment rates, and a severe lack of basic services 
(KZNHealth, 2017). 
ILembe Health District has four hospitals: Montebello District hospital, Stanger 
Provincial hospital, Umphumulo District hospital, and Untunjambili District hospital. 
The study included two Hospitals, Stanger Provincial hospital, and Umphumulo District 
hospital. Both hospitals belong to the ILembe health department in the public sector.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Map of the study area (http://www.kznhealth.gov.za/ilembe.htm).  
Data collection 
 
An explorative study using a semi-structured interviews with 132 informants (THPs, 
Patients seen by THPs, BHPs and patients seen either by BHPs alone or by both THPs 
and BHPs) was conducted on January 2018.  A total of 17 THPs and 15 patients seen by 
them were initially identified and interviewed by snowball sampling technique; while 100 
participants including 50 BHPs and 50 outpatients attending the two selected healthcare 
facilities. An interview face to face was used and the questionnaire form used for data 
Ilembe district  
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collection was specifically developed for the study in which were included in section A 
the participants’ address, age, gender, marital status, educational level, language spoken, 
occupation as well as in section B, information relating to the use of TM and their related 
conditions and in section C, information on any clinical outcomes including treatment 
failure and antimicrobial drug resistance from the concomitant use of TM and prescribed 
medicines. 
Data collection had three (3) phases. The first phase was done with THPs which were 
recruited purposively using snowball technique. Some of them were approached at their 
workplace during their business hours and other at their households and the only tool used 
was an interview questionnaire. Phase two was done with patients seen by THPs using 
snowball technique with their permission; they were asked whether they had used at the 
same time traditional and conventional medicine; to those that the answer was “yes”, they 
were asked if they could indicate which healthcare facility they had attended to in ILembe 
district. The third phase of the interview was with BHPs, they were recruited at the Clinic. 
BHPs were recruited purposively in the two selected healthcare facilities during their 
business operating hours. Finally, the fourth phase was conducted among outpatient, only 
those who were consulted by both THPs and BHPs and those who were attending the 
outpatient department. 
 
Statistical analysis 
Data collected from participants by interview were firstly entered and captured into Excel 
spreadsheets then all the responses from participants were grouped into thematic and then 
later analysed using Statistical Package for Social Sciences (SPSS), software version 25. 
Descriptive statistics including frequency and percentage were used to describe socio-
demographic characteristics of study participants and for expressing different variables 
or questions. 
 
Results 
Response rate 
This study enrolled 132 participants out of a targeted maximum of 150, yielding a 
response rate of 88.0%.  Respondents consisted of 17 out of 25 THPs, 15 out 25 patients 
seen by THPs, 50 BHPs and 50 outpatients seen by both THPs and BHPs in the two 
selected healthcare facilities. 
 
1. Socio-demographic characteristics of participants 
Table1 presents the socio-demographic characteristics of participants included in this 
study. Overall, the majority of participants included in this study were black African 
(116/132, 87.88%), female (86/132, 65.15%), unmarried (89/132, 67.42%), employed 
(84/132, 63.64%) and had attended at least secondary school (55/132, 41.66%). The 
median age was 35 years old with a standard deviation of 12.031(35 years old ± 12.031), 
while the minimum and maximum age were 18 and 76 respectively (Range 18 – 76). 
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Table 3.1 Socio-demographic characteristics of participants 
 
Variables 
                       
Sub category 
Frequency of THPs 
n=17 (%) 
Frequency of 
Patients seen by 
THPs n=15 (%) 
Frequency of BHPs 
n=50 (%) 
Frequency of Out patients 
seen by BHPs, n=50, (%) 
Total, N=132 (%)[95%CI] 
Ilembe 
district 
Municipality A 17 15 25(50.0) 25(50.0) 82(62.12)[53.84 - 70.4] 
Municipality B None None 25(50.0) 25(50.0) 50(37.88)[29.6 - 46.16] 
Gender 
 
Female 7(41.18) 12(80.0) 39(78.0) 28(56.0) 86(65.15)[57.02 -73.28] 
Male 10(58.82) 3(20.0) 11(22.0) 22(44.0) 46(34.85)[26.72 - 42.98] 
Race 
 
Black African 16(94.12) 15(100.0) 36(72.0) 49(98.0) 116(87.88)[82.31 - 93.45] 
Indian 1(5.82) None 11(22.0) 1(2.0) 13(9.85)[4.77 -14.93] 
White None None 2(4.0)  None 2(1.52)[-0.57 - 3.61] 
Mixed race None None 1(2.0) None 1(0.76)[-0.72 - 2.24] 
Occupation 
 
Employed  1(5.82) 9(60.0) 48 (96.0) 26(52.0) 84(63.64)[55.43 - 71.85] 
Unemployed  16(94.12) 6(40.0) 2(4.0) 24(48.0) 48(36.36)[28.15 - 44.57] 
Marital 
status 
 
Married  9(52.94) 2(13.33) 24(48.0) 5(10.0) 40(37.82)[29.55 - 46.09] 
Unmarried  8(47.06) 13(86.67) 25(50.0) 43(86.0) 89(67.42)[59.42 - 75.42] 
Widowed None None 1(2.0) 2(4.0) 3(2.27)[0.27 - 4.81] 
Educational 
level 
 
Illiterate  7(41.18) 2(13.33) None 1(2.0) 10(7.57)[3.06 - 12.08] 
Primary Sc. 6(35.3) 10(66.67) None 23(46.0) 39(29.54)[21.76 - 37.32] 
Secondary Sc. 3(17.65) 3(20.0) 24(48.0) 25(50.0) 55(41.66)[33.25 -50.07] 
Tertiary  1(5.82) None 26(52.0) 1(2.0) 28(21.21)[14.24 - 28.18] 
Language 
spoken 
 
IsiZulu 14(82.35) 15(100.0) 35(70.0) 49(98.0) 113(85.6)[79.61 - 91.59] 
Xhosa 2(11.76) None 1(2.0) None 3(2.27)[-0.27 - 4.81] 
English &/ 
Afrikaans 
1(5.82) None 14(28.0) 1(2.0) 16(12.12)[6.55 - 17.69] 
 Total 100% 
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2. Disease conditions treated and African traditional medicine used by THPs 
Table 2 presents self-reported disease conditions and African traditional medicines used 
by THPs for treating patients seen by them. The majority of THPs (64.70%, 11/17) have 
treated either one or more disease conditions such as period pains/abdominal cramps 
(Isibibho) and headache (Ubuhlungu ikhanda) (THP2, 3, 4, 6, 7, 8, 9, 10, 11, 14, 15). The 
following medicinal plants were reported by these eleven THPs for the management of 
the disease conditions above: Gumtree (Ugum-tree), Ikhowa mushroom (Umsilinga), 
Hypoxis hemerocallidea (Magic muthi or inkomfe), Senegalia burkei (Umkhaya), 
Hilliardiella aristata (Isibhaha), Spirostachys Africana sond (umtumbothi), Sutherlandia 
Frutescens subspecies Microphylla (Insiswa or Unwele).  
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 Table 3. 2  Self-reported disease conditions and African traditional medicine treated by THPs 
Translation of IsiZulu names taken from articles published by (Hutchings, 1996); (Pooley, 1993); (Ndlovu, 2009); (Ndlovu, 2013) and the website: pza.sanbi.org (Plantzafrica.com)
Variables Self-reported disease conditions treated Self-reported African traditional medicine used 
THP1 Open a person's womb (Isizalo), Fits (Isifo sokuwa), Shingles (Ibhande),  Tuberculosis (Isifo sofuba), 
influenza (Imfuluwenza), Gastritis (Ubuhlungu isisu), HIV infection (Igciwane lengculazi) 
Sutherlandia Frutescens subspecies Microphylla (Insiswa or Unwele) (boost the immune 
system), Isijula (Consider carefully deep: direct to the infection), Umbola (defeat the 
infection and makes it weak) 
THP2 Diarrhea (Isifo sohudo), stroke (unhlangothi), period pains/abdominal cramps/  (Isibhobo) Gumtree (Ugum-tree), Ikhowa mushroom (Umsilinga), goat (imbuzi), Inhambanella 
henriquesii (Umathungulu), marula tree, Sclerocarya birrea (Umganu), Aloe sp (Inhlaba) 
THP3 Shingles (Ibhande),  period pains/abdominal cramps/  (Isibhobo), Stroke (unhlangothi) Umsindo (Directed to the care of pain) 
THP4 Headache (Ubuhlungu ikhanda),  period pains/abdominal cramps/  (Isibhobo), Shingles (Ibhande), HIV 
infection (Igciwane lengculazi), punishment, assault (ukushangwa) 
English name (Ikhanda Eligatswayo), Hypoxis hemerocallidea (Magic muthi or inkomfe) 
THP5 Fits (Isifo sokuwa), Mego vuvukal kongawo, isisu segazi, Fufunyani (demons), Bladder or Abd. Pains 
(Ubuhlungu besisu) 
 
Not shared  
THP6 Headache (Ubuhlungu ikhanda),  Body itching/ sores on the body (Sores on the part the penis) (Uma 
unezilonda esithweni sangasese) 
Isilwane (animal, beast), Senegalia burkei (Umkhaya) and Setaria verticillata (Isinama), 
Sutherlandia Frutescens subspecies Microphylla (Insiswa or Unwele) 
THP7 Shingles (Ibhande),  menorrhea (Isisu), Headache (Ubuhlungu ikhanda), Mental trouble (Ukuhlushwa), 
ralwani 
Not shared 
THP8  period pains/abdominal cramps/  (Isibhobo), Inkwanju (cramps), amajagamba  Animal skin (sheddings of a snake, crocodile), Hilliardiella aristata (Isibhaha), Spirostachys 
Africana sond (umtumbothi) 
THP9 Bilharzia (Umkhaza isichnene), period pains/abdominal cramps/  (Isibhobo), Headache (Ubuhlungu 
ikhanda), 
Imkwangu, Hilliardiella aristata (isibhaha) 
THP10 Stroke (Unhlangothi), Shingles (Ibhande), Help clear womb to bare kids, Headache (Ubuhlungu 
ikhanda) 
Not shared 
THP11 Crazy people (Isifo sengqondo), Headache (Ubuhlungu ikhanda),  (where female is Bewitched and 
bleeds endlessly), urinary infections (Phayipi lomchamo) 
Mangifera indica (Ukwango=Umango), Sutherlandia Frutescens subspecies Microphylla 
(Insiswa or Unwele) 
THP12 Psychotic people (crazy) (Isifo sengqondo) and most emotional trips, and others diseases as, Gonorrhea, 
Cancer, Cold & Flu (Umkhuhlane) 
 Carpobrotus dimidiatus (Ikhambi)  
THP13 HIV infection (Igciwane lengculazi) and Cancer even crazy people Hypoxis hemerocallidea (Magic muthi or inkomfe), Liliaceae lancifolium spp, Wild 
(ilabatheka) 
THP14 Stomach Ulcers (Ubuhlungu isisu), Rashes ( Ukuqubuka), saws, Headache (Ubuhlungu ikhanda), 
Diarrhea (Isifo sohudo),  any diseases 
Spirostachys africana sond (Umtombothi), Sclerocarya birrea (Umganu), 
THP15 Problem with urinating, Headache (Ubuhlungu ikhanda), period pains/abdominal cramps/  (Isibhobo), 
Wounds (Isilofida) 
Inguduze, insumbili (help for witchcraft), Spirostachys Africana sond (Umtombothi), 
Hilliardiella aristata  (Isibhaka) (help for isibhobo), Umushlwa help for wounds 
THP16 Flu  & cold (Umkhuhlane), Diarrhea (Isifo sohudo), Vomiting (Uyahlanza ) & nausea, Infections, Any 
diseases 
Spiritual water used after praying, Liliaceae lancifolium Spp, Wild (Ilabatheka), Dombeya 
Rotundifolia, (Unhliziyo omkulu), Tetrademia ripania, Kamiaceae, (Ibozane: Ginger bush)  
THP17 Diabetes (Isifo sikashukela), Bilharzia (Umkhaza isichnene), HIV infection (Igciwane lengculazi), 
Bronchitis, Asthma, Bad spirits (Isifo sengqondo) 
isibunge, Khalimusi,   Hilliardiella aristata (Isibhaha), Ginger, Imboziso (help against flu), 
Hypoxis hemerocallidea (Magic muthi or inkomfe) 
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3. Self-reported disease conditions reported by patients seen by THPs 
Table 3 presents self-reported disease conditions reported by patients seen by THPS. The 
majority of patients (4/15) reported that they had cutaneous conditions such as sores on 
the body, body itching, wounds infection and rashes (Patients 5, 11, 12, 13). Three 
patients out of fifteen reported having respiratory problems such as chest pain and 
coughing (Patients 7, 9, 10).  
Table 3. 3 Self-reported disease conditions by patients seen by THPs 
 
 
 
 
 
 
 
 
 
 
 
 
Participants Self-reported disease conditions  Self-reported African medicines used 
Patient 1 Leg problem, foot was swollen Not shared 
Patient 2  Weakness Not shared 
Patient 3  Headache, no appetite Not shared 
Patient 4  Stressed out, Unbearable anxiety Water and prayer 
Patient 5  Sores on the body Prayer & Herbal medicine not shared 
Patient 6 Abdominal pain Herbal medicine not shared 
Patient 7 Coughing with blood, Chest pain Not shared 
Patient 8  Diarrhea, vomiting Herbal medicine not shared 
Patient 9 Stomach-ache, Coughing Herbal medicine not shared 
Patient 10 Respiratory problem, Chest pain, 
Coughing, Body pain 
Herbal mixtures (Plant, powder) not shared 
Patient 11 Body itching, Headache Herbal medicine not shared 
Patient 12 Body itching Not shared 
Patient 13 Wounds, Rashes Herbal mixtures (Plant, powder) not shared 
Patient 14 I was just sick, unwell Herbal mixtures (Plant, powder) not shared 
Patient 15 I was just sick, unwell Herbal mixtures (Plant, powder) not shared 
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4. Self-reported disease conditions and prescribed medicines by BHPs and 
outpatients 
Table 4 presents the frequency of disease conditions and prescribed medicines self-
reported by BHPs and outpatients. In total, 181 diseases were self-reported by 
respondents with almost half by BHPs (96/181, 53.04%) while the remainder of disease 
conditions were self-reported by outpatients (85/180, 46.96%). Overall, TB infection 
accounted for 28.18% (51/181) of all cases reported. Out of this proportion, 60.78% 
(31/51) were reported by the BHPs and 39.22% (20/51) were reported by outpatients. 
HIV infection accounted for 23.20% (42/181) of all cases reported overall.  Out of this 
proportion, 35.71% (15/42) were reported by BHPs and     64.29% (27/42) were reported 
by outpatients.  
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Table 3.4 Frequency of self-reported disease conditions and prescribed medicines by BHPs and outpatients 
NB: *There was more than one condition or disease reported by participants. 
Keynote: FDC: Fixed dose combination; BHP: biomedically healthcare professionals; TB: Tuberculosis, HIV: Human immunodeficiency virus;  UTI: Urinary tract infection; LRTI: Lower respiratory tract 
infection; STI: Sexually transmitted infection; URTI: Upper respiratory tract infection. 
 
 
 
Self-reported disease conditions Frequency of self-reported disease 
conditions 
Total (N=181) Self-reported prescribed medicine used 
Reported by BHPs Reported by Outpatients 
TB(Pulmonary, abdominal & meningitis) 31(17.13) 20(11.05) 51(28.18) Rifafour ( Ethambutol, Rifampicin, Pyrazinamide, Isoniazid), Pyridoxine 
HIV infection 15(8.29)  27(14.92) 42(23.21) FDC (TDF, EFV, 3TC/ABC, 3TC) 
Scabies 8(4.42) 4(2.21) 12(6.63) Fluconazole, Augmentin (Amoxicillin + Clavulanate), Benzyl benzoate 
Wound infections & Rashes 6(3.31) 3(1.65) 9(4.97) Clotrimazole cream, Fluconazole, Gentamycin, ciprofloxacin, Metronidazole 
Meningitis 5(2.76) 3(1.65) 8(4.42) Amphotericin B, Augmentin(Amoxicillin + Clavulanate), cephalexin,  ceftriaxone 
Malaria 4(2.21) None 4(2.21) Artesunate (2), CoArtem(2), Metronidazole, Bactrim (Trimethoprim and 
sulfamethoxazole, cotrimoxazole),  
Pneumonia  3(1.65) 4(2.21) 7(3.87) Ceftriaxone, Augmentin(Amoxicillin + Clavulanate), amikacin, tazocin 
(Piperacillin-tazobactam), Imipenem, meropenem, azithromycin,  
Respiratory problem, Coughing with blood, Chest infection 3(1.65) 4(2.21) 7(3.87) Augmentin(Amoxicillin + Clavulanate), Ceftriaxone, Ampicillin 
UTI 2(1.10) None 2(1.10) Augmentin(Amoxicillin + Clavulanate), ciprofloxacin, ceftriaxone 
STI 2(1.10) 3(1.66) 5(2.76) Azithromycin 
LRTI 2(1.10) None 2(1.10) Azithromycin, Augmentin(Amoxicillin + Clavulanate), Ceftriaxone 
Herpes zoster 2(1.10) None 2(1.10) Acyclovir, Augmentin (Amoxicillin + Clavulanate), ciprofloxacin 
Diarrhea, weakness & vomiting 1(0.55) 8(4.44) 9(4.97) Metronidazole, ciprofloxacin, Sorol citrate 
Body itching/ sores on the body(Sores on the part the penis)  1(0.55) 2(1.11) 3(1.65) Augmentin(Amoxicillin + Clavulanate), Fluconazole 
Skin disease 1 (0.55) None 1(0.55) Augmentin(Amoxicillin + Clavulanate), cloxacillin 
URTI 1(0.55) None 1(0.55) Amoxicillin 
Influenza infection 1(0.55) None 1(0.55) Augmentin(Amoxicillin + Clavulanate), ceftriaxone, cephalexin 
Measles 1(0.55) None 1(0.55) Fluconazole 
Herpes snapper 1(0.55) None 1(0.55) Acyclovir 
Chickenpox   1(0.55) None 1(0.55) Amikacin 
Others(Non-communicable diseases: Headache, Epilepsy) 5(2.76) 6(3.31) 11(6.10) Non prescribed antimicrobials(Panado,  Allergex) 
None response None  1 (0.55)  None 
Total 96(53.0.4%) 85(46.96%) 181(100%)  
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5. Perception of BHPs and outpatients on the use of TM and prescribed 
medicines  
Table 5 presents the frequencies of responses obtained from respondents on the use of 
TM. To the question “Have you ever treated infectious diseases in the past 3 months? 
/have you had infectious diseases in the past 3 months?” Overall, 89% (89/100) of 
respondents (BHPs (39/100, 39%) and outpatients (50/100, 50%) have reported infectious 
diseases. Out of this proportion, 43.82% of treated infectious diseases were reported by 
BHPs (39/89) and the remainder of infectious diseases were reported by outpatients 
(50/89, 56.18%). To the question “Are your patients satisfied with the treatment received 
for the above infectious diseases? / Are you satisfied with the treatment received for the 
above infectious diseases?" the majority of respondents (90/100, 90%) either BHPs 
(46/90, 51.11%) and outpatients (44/90, 48.88%) responded that they were satisfied with 
the treatment. This question was asked to respondents “What do you think about the 
treatment administered to patients? / what do you think about the treatment administered 
to you?” overall 88% of both BHPs and outpatients (88/100) responded that the treatment 
was “Effective” 
To the question “Have you ever treated other patients referred to you by THPs? / Have 
you ever used traditional medicine in the past 3 months?” A few numbers of respondents 
(BHPs and outpatients) (29/100, 29%) that they received patients referred from THPs 
(BHPs) and a few other numbers of outpatients reported that they have been referred from 
THPs to BHPs. Furthermore, to next question asked only to outpatients “Can TM fight 
infectious diseases?” Half of them responded affirmatively (25/50, 50%) and only 34% 
of outpatients (17/50) responded that “sometime”. Another question was asked only to 
outpatients “What do you think about the use of TM to treat your infectious diseases?” 
Overall 30% of outpatients (15/50) responded that “TM can fight infectious diseases if 
using the right dose and the right medicinal plant.” To the question asked only to 
outpatients “What do you think of combining various medicines to treat the same 
infectious diseases? The majority of them (14/50, 28%) responded that “They can fight 
both completely the same disease” another question was asked to outpatients “Have you 
ever combined at the same time TM and prescribed medicines?” Overall 20% of 
outpatients (10/50) responded that “I stopped with TM when I started with prescribed 
medicine” and 20% other outpatients (10/50) responded that “Doctor or THP could not 
allow the use of both” 
The following question was addressed only to BHPs “What do you think about drug-drug 
interactions for those patients using concurrently TM and prescribed antimicrobial 
medicines? The majority of BHPs (10/50, 20%) responded that “This could result in drug 
resistance especially resistance to antibiotics” and 18% of them (9/50) responded that 
"Most of the patients came to the clinic with several complications such as kidneys failure 
or liver failure, vomiting, diarrhea and jaundice after using either TM alone or in 
combination with prescribed medicine, since TM is not safe at all.” Another question was 
asked only to BHPs “Can I talk to the concerned patients using both TM and prescribed 
antimicrobial medicines?” the majority of BHPs (37/50, 74%) did not give their 
agreement. 
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Table 3. 5 Perception of BHPs and outpatients on the use of TM and prescribed medicines  
Questions  Responses BHPs 
(n=50) 
Outpatients  
(n=50) 
Total (N=100) 
Have you ever treated infectious diseases in the past 3 months? / Have you 
had infectious diseases in the past 3 months? 
Yes 39 50 89 
No 11 None 11 
Are your patients satisfied with the treatment received for the above 
infectious diseases? / Are you satisfied with the treatment received for the 
above infectious diseases?  
Yes 46 44 90 
No 4 6 10 
What do you think about the treatment administered to patients? / What 
do you think about the treatment administered to you?  
Effective               40 44 88 
No effective 4 6 10 
According to guidelines 6 None 6 
Have you ever treated other patients referred to you by THPs? / Have you 
ever used traditional medicine in the past 3 months? 
Yes 7 22 29 
No 43 28 71 
 
Can TM fight infectious diseases? 
Yes NA 25  25 
No NA 8  8 
Sometimes NA  17  17 
What do you think about the use of TM to treat your infectious diseases?  TM can fight infectious diseases if using the right dose and the right medicinal plant NA 15(30%) 15 
It can heal but not for infectious diseases like HIV or TB NA 11(22%) 11 
It depends on the believing  NA 6 6 
It is so strong and harmful, then it can bring any Intoxication or damage to the body NA 6 6 
No, it cannot cure infectious diseases NA 4 4 
As African, we believe in TM NA 2 2 
It can treat but with many side effects NA 1 1 
I advise both TM and prescribed, but THP and BHP must be in touch to avoid any side 
effect 
NA 1 1 
I do not believe in TM as a Christian NA 1 1 
Only qualified doctors can treat Infectious diseases NA 1 1 
No idea NA 2 2 
What do you think about combining various medicines to treat the same 
infectious diseases?  
They can  fight both completely the same disease NA 14(28%) 14 
Since it is the doctor's idea then it is fine NA 11(22%) 11 
At the hospital they give us various medicine for only one disease, then combining is 
good  
NA 5 5 
Not good, the treatment can fail or any Intoxication NA 5 5 
Many side effects and complications can happen NA 4 4 
It depends on everyone's believes  NA 3 3 
Medicines can interact with each other  NA 3 3 
It depends on everyone's experience(THP or BHP)  NA 2 2 
The disease can become worse  NA 1 1 
No idea NA 2 2 
I stopped with TM when I started with prescribed medicine NA 10 (20%) 10 
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Have you ever combine at the same time TM and prescribed medicines for 
infectious diseases?nes 
Doctor or THP cannot allow the use of both NA 10(20%) 20 
I never combine since TM brought bad effect, I stopped immediately NA 9 9 
I never used both NA 9 9 
I stopped TM before to start with prescribed medicines NA 2 2 
I stopped with TM when I started with HIV medicine NA 2 2 
I stopped TM before since it did not heal me  NA 2 2 
They must be used separated with a gap of time NA 2 2 
I could not combine since they can bring many complications  NA 1 1 
I stopped TM when I got diarrhea  NA 1 1 
I stopped with TM when I knew my HIV status NA 1 1 
I used TM alone for Diarrhoea NA 1 1 
 
 
 
 
 
 
 
 
 
What do you think about drug-drug interactions for those patients using 
concurrently TM and prescribed antimicrobial medicines? 
Can result in drug resistance especially resistance to antibiotics 10(20%) NA 10 
Most of the patients come to the clinic with several complications such as Kidneys failure 
(liver failure), vomiting, Diarrhoea, and jaundice after using either TM alone or in 
combination with prescribed medicine, Since TM is not safe at all.  
9(18%) NA 9 
Combing TM with Western medicines must be discouraged since the desired effect of 
medicines can be increased in producing many complications. 
6 NA 6 
Delay of the healing process with prescribed medicines because of TM used (Drug-
interaction)  
5 NA 5 
Both can inhibit each other, so treatment failure can happen  4 NA 4 
I think  any interaction like toxicity or Treatment failure can happen 2 NA 2 
Awareness should be given to the patient when combining 2 NA 2 
Use either TM alone or western medicines alone. 2 NA 2 
Since it is a free country, then patients are free to use medication of their choice according 
to their different cultural background 
2 NA 2 
Collaboration might be between THPs and BHPs to avoid any intoxication 2 NA 2 
Use either TM alone or western medicines alone 1 NA 1 
THPs must be registered before giving medicine to patients 1 NA 1 
Difficult to assess notice as patients do not report herbal use  1 NA 1 
Drug resistance can happen because TM is not registered in MCC 1 NA 1 
HIV or TB patients who take both, their viral load became high  1 NA 1 
I never encounter, come across those patients 1 NA 1 
Can I talk to the concerned patients using both TM and prescribed antimicrobial 
medicines? 
Yes 13 (26%) NA 13 
No 37 NA 37 
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6. Self-reports of clinical outcomes following concurrent use of both TM and 
prescribed medicines by BHPs and outpatients 
Table 6 presents clinical outcomes reported by BHPs and Outpatients following the 
concurrent use of both TM and prescribed medicines.  
To the question asked only to BHPs “Are you aware of patients using both THPs and 
BHPs for infectious diseases?” The majority of BHPs affirmed that they were aware of 
patients using both TM and prescribed medicines (38/50, 76%). A question was asked to 
respondents “Have you ever registered some cases of drug-drug interactions (TM and 
prescribed medicines)?” A minority of respondents including both BHPs and outpatients 
(28/100, 28%) indicated that they had registered some cases of drug-drug interactions. 
Another question was asked to respondents about “types of interactions found between 
TM and prescribed medicines”. Only 11% of BHPs and outpatients (11/100) responded 
that “The desired effect increases”. 
To the question “Have you ever registered some cases of adverse effects when combining 
both TM and prescribed medicines?” A small number (25/100, 25%) of both respondents 
BHPs and outpatients (75/100) registered some cases of adverse effects. A question was 
further asked to probe the types of adverse effects experienced by patients for combining 
both TM and prescribed medicines. Diarrhea (11/100, 11%) and kidney failure (7/100, 
7%) were mainly reported as adverse effects experienced by respondents. The majority 
of BHPs and outpatients responded that “Drug interactions, resistance to treatment, 
failure of TM and intoxication could occur when combining TM and prescribed 
medicines.” Furthermore, they said that medicines would interact with each other and 
patients became very ill with symptoms such as convulsion and unconsciousness (16/100, 
16%)”. 
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Table 3.6 Perceptions of BHPs and outpatients on the clinical outcomes from the use of both TM and prescribed medicines  
Questions Responses BHPs 
(n=50) 
Outpatients 
(n=50) 
Total (N=100) 
Are you aware of patients using both THPs and BHPs for infectious 
diseases?  
Yes 38(76%) NA 38 
No 12 (24%) NA 12 
Have you ever registered some cases of drug-drug interactions 
when combining both TM and prescribed medicines?  
Yes 17 (17%) 11 (11%) 28 (28%) 
No 33 (33%) 39(39%) 72(72%) 
 
If yes, which medicines (TM and prescribed medicines) were 
involved? 
Not determined  33 (33%) 40(40%) 73(100%) 
TM 17(17%) 8(8.0%) 25(25%) 
HIV medicine None 1(1.0%) 1(1.0%) 
TB medicine None 1(1.0%) 1(1.0%) 
 
Types of interactions between TM and prescribed medicines 
The desired effect increases 11(11%) None 11 
The desired effect decreases 6(6.0%) 1 7 
Intoxication 2 5(5.0) 7 
MDR None 2 2 
Treatment failure of TM None 3 3 
Have you ever registered some cases of adverse effects when 
combining both TM and prescribed medicines?  
Yes 13 12 25 
No 37 38 75 
 
 
If yes, which medicines (TM and prescribed medicines) were 
involved? 
TM NA 7 7 
TB medicines NA 2 2 
HIV medicines NA 1 1 
HIV medicines associated with TB medicines NA 1 1 
HIV medicines associated with Painkillers  NA 1 1 
 
Kind of adverse effects 
Diarrhea  7 4 11 
kidneys failure (liver injury)  7 None 7 
Jaundice 6 None 6 
Vomiting and weakness 4 6 10 
Rashes 3 2 5 
Tiredness and loss of energy 2 2 4 
Loss of appetite 2 2 4 
Electrolyte in balance 1 None 1 
Confusion 1 None 1 
Convulsion 1 None 1 
A headache  1 1 2 
Dizziness None 1 1 
Penis part changed color  None 1 1 
 
 
 
 
Drug interaction or drug resistance (Failure of TM, any intoxication), medicines will interact with 
each other and patients become very ill (Convulsion, unconsciousness)  
16 None 16 
Never experienced because patients hide the use of TM 12 None 12 
Kidneys failure (renal failure), drug-induced, diarrhea, vomiting, and death  11 None 11 
Delay of treatment, unsatisfactory of treatment, less effectiveness of treatment and death 11 None 11 
Qualified doctors can explain it well None 7 7 
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What is the effect experienced by patients for combining both TM 
and prescribed medicines? / What is the effect experienced by you 
for combining both TM and prescribed medicines?  
I will not recover if combining  None 6 6 
Interaction can occur between TM prescribed medicines None 6 6 
The medicine effect can increase and damage the body None 6 6 
To avoid any Intoxication, this must not be allowed None 6 6 
The disease can become worse None 5 5 
They can interact with each other  None 5 5 
TM was not used at the same time with western medicine None 1 1 
No idea None 8 8 
 
  
53 
 
7. Perceptions of THPs and patients seen by them on the use of TM 
Table 7 presents the perceptions of both THPs and their patients on the use of TM. A 
question on diagnosis was asked to THPs “How do you decide whether you are treating 
a viral or bacterial infection?”  Overall 35.29% of THPs (6/17) responded that “spiritual 
search, dreams and ancestor guidance (Idlozi)” were the way for them to determine 
whether it was about viral or bacterial infection. Furthermore, four THPs (4/17, 23.52%) 
out of those number responded that “they did not cure viral infections, after seeing their 
patients’ symptoms they referred them to the hospital”.   
To the question “What basic ideas (philosophy) are you using before you decide on the 
treatment pattern?” A few THPs (5/17, 29.41%) indicated that they learned from 
ancestors and elders.  Dreams and calling from ancestors were as well reported as a way 
to determine their treatment pattern (3/17, 17.64%).  Furthermore, another question was 
asked to THPs about “Are your patient(s) satisfied with your healing?” Most of THPs 
(14/17, 82.35%) responded that their patients were satisfied with the treatment received. 
More than half of patients seen by THPs (8/15, 53.33%) `have confirmed that they felt 
relieved by the treatment received from THPs.  Another question asked to THPs “Can I 
talk to your patient(s)?” The majority of THPs (11/17, 64.70%) did not agree and gave 
as a reason that their patients' life was private and confidential (7/11, 63.63%).  
To the question asked to patients “Why did you choose TM for your condition?” Almost 
half of the patients (6/15, 40%) seen by THPs responded that “TM healed them before, 
they believed in it then it was fast and less costly”. Furthermore, a small number of same 
patients (3/15, 20%) seen by THPs responded that “They were told about TM as well as 
because the hospital was far”. A similar question was asked to patients “Did you use 
traditional medicine previously?” The majority of patients (11/15, 73.33%) seen by THPs 
agreed that they used TM before. In addition, another question was asked to patients 
about” Did the THPs use some prayers, things, songs, spiritual rituals in addition?” Most 
of the patients seen by THPs (11/15, 73.33%) affirmed that THPs did some rituals upon 
them such as “Prayer to ancestors” (6/15, 40%).
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Table 3. 7 Perceptions of THPs and patients seen by them on the use of TM 
Questions Responses THPs Patients 
 
 
 
How do you decide whether you are treating a viral or bacterial infection? 
Spiritual search, dreams and ancestor guidance (Idlozi) 6 NA 
Symptoms from patients then I do not cure viral infection, in case I refer to the hospital 4 NA 
Certain explanations, symptoms, medical records, examination (Ukuhlola) from the patients 3 NA 
First I send people to the hospital for the blood test, then I treat according to the hospital results  2 NA 
Symbols showed by ancestors 1 NA 
Disease revealed by the holy spirit 1 NA 
 
 
 
 
 
What basic ideas (philosophy) are you using before you decide on the treatment 
pattern? 
I learned from ancestors and elders  5 NA 
Dreams  and calling from ancestors 3 NA 
Practical experience for many years and traditional searching 2 NA 
Talents and ancestors calling 2 NA 
The philosophy is to talk to elders that have passed away 2 NA 
Revelation from the holy spirit 1 NA 
First seek help from the hospital then here(THP)  1 NA 
There is a school where we are taught 1 NA 
Do your patient(s) satisfied with your healing?  Yes 14 NA 
Not at  the exact time 3 NA 
Can I talk to your patient(s)? Yes 6 NA 
No 11 NA 
 
Any reason(if the answer is NO) 
My patients' life are private and confidential  7 NA 
I lost their contacts 4 NA 
 
 
Why did you choose TM for your condition? 
TM healed me before, I believe in it then it is fast and less costly NA 6 
I was told about it NA 3 
The hospital was far NA 3 
THPs are more  confident than doctors, then the healing is fast NA 2 
Because the doctor failed to heal me  NA 1 
Did you use traditional medicine previously? Yes NA 11 
No NA 4 
Did the THPs use some prayer, things, songs, spiritual rituals in addition? Yes NA 11 
No NA 4 
 
 
 
Specify those practices 
Prayer to ancestors NA 6 
He  screamed to the spirit and sung  NA 1 
He kept quiet for a moment when he prayed  NA 1 
He rang the bell then prayed NA 1 
He turned around by singing NA 1 
Attended the services, when they praise and pray NA 1 
None NA 4 
 
 
 
How do you feel after treatment (the issue)?  
Relieved NA 8 
Unwell NA 4 
Relieved but with side effect NA  2 
Nothing changed, he referred me to the hospital NA 1 
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8. Self-report of clinical outcomes following concomitant use of TM with 
prescribed medicines by THPs and Patients seen by them  
Table 8 presents the general perception of THPs and patients seen by them on the use of 
TM. To the question “What type of treatment are you using to treat your patients with 
infectious diseases?” A small number of THPs (5/17, 29.41%) responded that their 
information was “confidential” and the same question was also asked patients (9/15, 60%) 
seen by them who also indicated that they did not know the medicines used by their THPs 
since THPs did not share their knowledge. The following question was asked to 
respondents “Do both THPs and their patients' mix sometimes different herbs for 
treatment in case of different infectious diseases?” Overall, of both THPs and their 
Patients (22/32, 68.75 %) affirmed that they mixed different herbs in case of infectious 
diseases.  To the question about any reason for mixing different herbs, the majority of 
THPs (10/17, 58.82%) responded that “each illness had its own plants”, so they could be 
combined. Each Ikhambi (medicinal plant) had its own condition /infection; the intakes 
are different so medicines do not interfere; THPs could combine until they find a solution; 
people came with certain different cases, then THPs must treat by mixing herbs”.  
Moreover, another question asked to both THPs and patient “Do your patients combined 
TM with prescribed medicines? Most of them (21/32, 65.62%) responded that they were 
aware that their patients used to combine TM with prescribed medicines.  Patients seen 
by THPs were asked the following question: “Do you consult also BHPs for the same 
problem?” Less than half of patients seen by THPs (6/15, 40%) responded that they 
consulted both THPs and BHPs.  
To the question about any reason for” combining TM with prescribed medicines for 
infectious diseases”, less than half of THPs (8/17, 47.05%) responded that in case of any 
interaction such as vomiting and coughing they did refer patients to BHPs. In case of 
treatment failure or any other complications, THPs referred 100% of their patients to 
BHPs. In addition, in case of any medicine from THPs did not work; THPs are not 
allowed to donate water or blood or any other treatment that may lead to death of patients. 
Thus it is good to work hand to hand or to collaborate between BHPs and THPs.  
To the question “Do you ever register some cases of adverse effects after mixing TM with 
prescribed medicines for infectious diseases?” Less than half of THPs and patients 
(14/32, 43.75%) responded that they had experienced adverse effects. Vomiting, 
dizziness, diarrhea, and weakness were some of the adverse effects reported by THPs 
(3/17, 17.64%) and one patient (1/15, 6.66%). The following question was asked to THPs 
“What is your thought about interactions for using at the same time TM with conventional 
medicines?”  Few THPs (3/17, 17.64%) responded that “interactions were good 
especially when you are not sure with one medicine”, the same question was asked to 
patients seen by THPs, a few patients (4/15, 26.66%) responded that “disease could get 
worst.” Another question was asked to THPs “According to you, what can occur if the 
patient takes at the same time TM and conventional medicine?” Less than half of THPs 
(6/17, 35.29%) responded that “nothing bad could happen if patients respected the time 
lapse between the two treatments”. 
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Table 3. 8 Perceptions of THPs and patients seen by them on the clinical outcomes from the use of both TM and prescribed medicines 
Questions 
 
Answers THPs Patients  Total  
 
 
 
 
 
 
 
 
 
What type of treatment are you using to treat your patients?/ 
Which type of TM, your THP has used to treat you? 
Confidential 5 None  5 
Plants and animal parts 4 None  4 
Not using plants 3 None  3 
It depends of the problem 2 None  2 
Most of the knowledge the ancestors had, it was from plants (Leaves, crops,..) 1 None  1 
crops, leaves 1 None  1 
Leaves, roots 1 None  1 
He used herbal (Muthi), but I do not know None  9 9 
No idea, it is THPs own secret None  3 3 
I was unconscious, I cannot know None  1 1 
Wangi caba (cut with a bleed), herbs, impepo, pleading with ancestors None  1 1 
Water and prayer None  1 1 
In case of a different problem, does the THP mix also different 
herb to treat you? Are you also sometimes mixing different herbs 
for your patient in case of a different problem? 
Yes 11 11 22 
No 6 4 10 
 
 
 
Reasons  for mixing both TM and prescribed medicines for 
infectious diseases 
Each illness has its own plant, so they can be combined 2 NA 2 
Each khambi has its own things/infection 2 NA 2 
The intakes are different so medicines do not interfere 2 NA 2 
I can combine until I find a solution 2 NA 2 
People come with certain different cases of the problem, then you must treat by mixing herbs 2 NA 2 
Each medicine has its place to work 1 NA 1 
I mix 3 or 4 medicines when I am  not sure with the diagnostic 1 NA 1 
When I am not sure with the patient's problem 1 NA 1 
None 4 NA 4 
 
Do your patients combined TM and prescribed medicines for 
infectious diseases? / Do you use to consult also BHPs for the same 
problem?  
Yes 15 6 21 
(65.62%) 
No 2 5 7 
Yes but not for the same problem None  1 1 
Yes I did before to consult the THP None  1 1 
Yes Referred by the THP None  2 2 
 
 
 
 
Reasons for combining both TM and prescribed medicines for 
infectious diseases 
In case of any interaction (vomiting  or coughing), I do refer them  1 NA 1 
In case of treatment failure or complication, I refer 100% of patients to doctors 1 NA 1 
In case that THP's medicine does not work 1 NA 1 
It is a norm now. We were taught, we cannot donate water or blood that leading to death 1 NA 1 
It is good to work hand to hand(a collaboration between BHP and THP)  1 NA 1 
They do combine but not for the same problem 1 NA 1 
only in case of over illnesses 1 NA 1 
There are medicines only for specific disease, so prescribed medicine will not work after using TM  1 NA 1 
None 9 NA 9 
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Do you ever register some case of adverse effects after mixing 
that? 
Yes 8 6 14 
No 9 9 18 
 
 
 
(If Yes) List them 
Weakness and vomiting 3 1 4 
Dizziness and weakness 2 1 3 
Diarrhea and vomiting 2 None  2 
Allergies 1 None  1 
Chest pain None  1 1 
The disease went worst None  1 1 
loose of sight None  1 1 
Nausea None  1 1 
None 9 9 18 
 
 
 
 
What is your thought about interaction when using at the same 
time TM and Conventional medicine for infectious diseases? 
The disease can get worst  None 4 4 
They can interact with each other  None 2 2 
The medicines effect can either increase or decrease None 1 1 
The treatment can either be successful or fail None 1 1 
There must be a time gap in their use None 1 1 
They both treat and they do not clash None 1 1 
Side effects can occur None 1 1 
You can get intoxicate None  1 1 
Interaction is good especially when you are not sure with one medicine 3 None 3 
A mutual relationship is good. We do not have the equipment to check the minor things that play a big role in a person 
life 
2 None 2 
It is good for fighting completely the diseases but this  treatment must be stopped in case of adverse effect 2 None 2 
The interaction is good as long as there is a time lapse  2 None 2 
Patients must not take both, at least his BHP and THP must be in known. 1 None 1 
Since we do not have the same knowledge, we should help each other(TM and Prescribed medicine) 1 None 1 
No idea 3 3 6 
Patients get heal but there must be a mutual relationship between THP and BHP 1 None 1 
The interaction is good. BHP cannot treat a specific disease that needs an ancestor intervention. 1 None 1 
We cannot heal disease instantly, there is a process. So BHP and THP must collaborate 1 None 1 
 
 
 
According to you, what can occur if the patient takes at the same 
time TM with conventional medicine? 
If they respect the time lapse, nothing bad can happen 6 NA 6 
Intoxication 3 NA 3 
It depends on their dosage, but any complication must be avoided  3 NA 3 
Medicines can interact 3 NA 3 
No Idea 1 NA 1 
There must be a mutual relationship, there is something that I can heal  and some other that the doctor can also heal  1 NA 1 
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DISCUSSION OF THE RESULTS 
THPs and their Patients 
This study was conducted in the ILembe district, South Africa on experiences from BHPs, 
outpatients, THPs and patients seen by them. The aim of the study was to establish 
whether any antimicrobial resistance and treatment failure could occur among patients, 
attending outpatient departments of selected healthcare facilities, who used concurrently 
prescribed antimicrobial medicines and TM. 
This study found a small number of medicinal plants used by THPs such as Spirostachys 
Africana sond (Umtombothi), Hypoxis hemerocallidea (magic muthi or inkofe) and 
Sutherlandia frutescens (Insiswa or Unwele). Although the majority of THPs could not 
reveal the specific recipe used for each disease condition treated with the listed plants 
above; a few THPs indicated that they used Sutherlandia Frutescens for “boosting the 
immune system.” THPs in this study also used Hypoxis hemerocallidea and Sclerocarya 
birrea (Umganu) for treating diarrhea (Isifo sohudo) and HIV infection (Igciwane 
lengculazi). The use of Hypoxis hemerocallidea against infectious diseases has been 
reported previously in another study for the treatment of sexually transmitted 
infections(De Wet et al., 2012). Another study reported the use of Hypoxis hemerocallidia 
and Sutherlandia frutescens for enhancing the immune system and may have antiviral 
properties (Awortwe et al., 2013, Mugomeri et al., 2016). Sclerocarya birrea (Unganu 
plant) has been reported having a pharmacological property against sexually transmitted 
infections such as gonorrhea (De Wet et al., 2012). In some African countries, the same 
plant was used in the management of human ailments, such as diarrhea, dysentery, and 
others (Louis et al., 2018). 
This study found that 65.62% of THPs and their patients (21/32) mixed different herbs 
for the treatment of infectious diseases. This finding may be supported by another study 
conducted in Portugal (Freitas et al., 2013) which reported the synergistic enhancement 
of antimicrobial compounds from medicinal plants. However, respondents from this study 
reported that they had experienced adverse effects such as vomiting, dizziness, diarrhea, 
and weakness when mixing different herbs for the management of their infectious 
diseases. Compared to another study, respondents expressed negative attitudes towards 
the use of TM in conjunction with prescribed medicines by showing that TMs were most 
of the time harmful especially when mixing them with ARVs, they ended to death or any 
other complications (Weintraub et al., 2018).  
In this study, respondents agreed that when combining both TM and prescribed medicines 
for infectious diseases, interactions and adverse effects may result and if there is no 
respect of time lapses between the two medicines, the infectious disease may get worse. 
Perceptions from respondents in this study may be supported by statements such as TM 
and prescribed medicines could coexist and complement each other (Giovannini et al., 
2011, Calvet-Mir et al., 2008). In the same line, another study done in Brazil reported that 
people in the local community relied on both TM and prescribed medicines to treat 
diseases of all categories including infectious diseases (Zank and Hanazaki, 2017). 
BHPs and outpatients 
This study found that the majority of disease conditions were infectious diseases 
(169/180, 93.88%) with mainly TB infection (51/181, 28.33%) and HIV infection 
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(42/180, 23.33%) reported in Table 4 above. This may be supported by a previous study 
done in KwaZulu-Natal province which found that KwaZulu-Natal province had the 
highest  prevalence of HIV infection in South Africa (Gómez-Olivé et al., 2013); a 
recently published report on the prevalence of HIV infection in South Africa showed that 
KwaZulu-Natal province was the most prevalent province (Approximatively 26.6 %) 
among the top four high HIV-prevalent provinces in South Africa (Statistics South Africa, 
2018). 
Respondents (30%, 15/50) from this study perceived that TM can fight infectious diseases 
if using the right dose and the right medicinal plant; in addition, they responded that TM 
is associated with prescribed medicines could fight completely infectious diseases. In 
contrast, Weintraub et al.,(2018) disagreed in showing that the majority of respondents in 
his study opposed the concurrent use of TM and prescribed medicines for the management 
of HIV infection and they believed that ARVs were the most effective option for treating 
HIV infection.  In line with the findings of this study, TM remains the framework and 
cannot be ignored against the management of infections. Accordingly, many authors 
suggested  for collaboration between BHPs and THPs by respecting local expertise in 
managing infectious diseases (Green and Ruark, 2016, Gqaleni et al., 2011)    
Outpatients (20/50, 40%) in this study reported that they stopped with using TM when 
started with prescribed medicine or when they knew their  HIV status because BHPs 
would not allow the use of both. A study done previously in 2010 showed that the use of 
TM usually decreases among patients after ARV initiation (Peltzer et al., 2010); more 
studies reported that traditional medications provided good results, despite their side 
effects and toxicity (Leone et al., 2015, Anwar et al., 2007). TM and prescribed medicines 
if used concurrently should be used wisely per avoidance of any interactions and adverse 
effects such as kidney failure which mostly reported the present study.  
Respondents in this study including BHPs and outpatients reported that combining TM 
and prescribed medicines for infectious diseases may result in drug resistance especially 
resistance to antibiotics and they highlighted that the majority of patients came to the 
clinic with several complications such as kidneys failure, vomiting, diarrhea and jaundice 
after using either TM alone or in combination with prescribed medicines. Similar studies 
were conducted in the UK and in Ethiopia showing that the lack of collaboration between 
health practitioners has an impact on treatment failure. BHPs always have negative 
perceptions about TM which discourage patients from sharing information on the use of 
TM  which result in adverse effects and interactions on patients health due to the toxicity 
of TM used (Mekuria et al., 2018, Barnes, 2003). From these experiences stated by 
respondents in this study, authors may admit that having conventional medicines and TM 
at the same time may interfere or may result in damaging some organs, failure of the 
treatment as well as modifying drugs pharmacological action.  
Strengths and limitations of the study 
This was a mixed method approach study using both qualitative and quantitative as study 
design. This study was a triangulation study including four (4) types of participants, 
namely THPs, patients seen by THPs, BHPs, and outpatients. This study had a few 
limitations. This was a survey with self-reports collected from respondents.  There was 
neither observation of THPs in their practices nor experimentations conducted by 
researchers. No matching of information between BHPs and patients seen by them; 
although this study matched information from THPs and a few patients seen by them. The 
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concurrent use of TM and prescribed antimicrobial was under-reported by participants 
because of embarrassment or belief that their medical providers were against TM use or 
their information could be divulgated  (Puoane et al., 2012). The majority of medicinal 
plants used by THPs for infectious diseases or other disease conditions were not reported 
by them and kept as a secret. However, results cannot be generalized to the entire 
population of THPs, patients seen by them, BHPs and outpatients in the entire province 
of KwaZulu-Natal and South Africa.  
Conclusion 
This study presented different perceptions from THPs, BHPs and their patients on 
medicinal plants used concurrently with prescribed antimicrobial medicines and their 
effects on antimicrobial resistance and treatment failure. A small number of medicinal 
plants were reported with antibacterial and/or antiviral properties. THPs and their patients 
confirmed that they combined medicinal plants for a positive result. Cases of interactions 
and adverse effects were reportedly referred by THPs to the nearest hospital or clinic. 
However, patients seen by either BHPs or THPs confirmed that they stopped with TM 
when they started with prescribed antimicrobial medicines. The majority of BHPs 
reported that adverse effects such as kidney failure, vomiting, and jaundice were the most 
common clinical outcomes among patients who used either TM alone or in combination 
with prescribed medicines. Further studies are needed in other parts of South Africa to 
investigate the effects of concurrent use of traditional medicine and prescribed 
antimicrobial medicines. Furthermore, studies are needed to investigate bidirectional 
referral systems between THPs and BHPs. 
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ABSTRACT 
Background: Antimicrobial resistance (AMR) is a major origin or cause of treatment 
failure and is largely responsible for the declining in eradication rates of infectious 
diseases worldwide. AMR in South Africa is driven by many factors such as the careless 
use of prescribed antimicrobial medicines and the use of traditional medicine, with the 
result that there is always the danger of misadministration, interaction, and toxicity. This 
study aimed at determining whether any antimicrobial resistance and/or treatment failure 
occurred among patients attending out-patient departments in selected healthcare 
facilities and who use concurrently traditional medicine with antibiotics and/or antiviral 
medicines in ILembe district, KwaZulu- Natal. 
Methods: This study was a cross-sectional descriptive study using medical chart review 
among patients attending the outpatient department in two public healthcare facilities 
between February and March 2018. Antimicrobials prescribed alone or in association 
with other medicines and concurrent use of traditional medicine were assessed and 
reported using descriptive statistics. Where applicable, associations were carried out; a p-
value ˂0.05 was estimated as statistically significant. 
Results: Four hundred (400) outpatients’ medical records were documented from two 
different municipalities, many participants had viral infections (194/400, 48.50%). 
Overall, 12% of participants (48/400) had documented negative clinical outcomes with 
adverse effects (30/48) and interactions (18/48). A few participants (15/400, 3.75%) had 
used traditional medicine in conjunction with prescribed medicines. Among those who 
used both traditional medicine and prescribed medicines, the majority (80%, 12/15) had 
documented adverse effects due to the concurrent use of traditional medicine and 
prescribed medicines. After adjustment, documented adverse effects and interactions 
were significantly more likely due to the use of traditional medicine (AOR = 0.01, 95% 
CI = 0.001-0.05) and (AOR = 0.21, 95% CI = 0.37-1.23) respectively. 
Conclusion: Traditional medicine was sparingly used in conjunction with prescribed 
antimicrobials for viral and bacterial/fungal infectious diseases. However, adverse effects 
and interactions such as herbal intoxication, persistent rashes, and treatment failure were 
documented in few medical chart records among outpatients attending the two selected 
healthcare facilities. Further studies are needed to investigate the effects of concurrent 
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use of traditional medicine from perspectives of traditional healers and biomedically 
healthcare professionals.  
 
KEYWORDS: Antimicrobial resistance - Treatment failure- Traditional Medicine - 
Bacterial and viral infections. 
 
BACKGROUND  
Antibiotic-resistant microorganisms as “nightmare bacteria” represent a global menace 
[1]. Some microorganisms have become resistant to multiple antimicrobial classes, which 
means that infectious diseases caused by resistant bacteria are now common [2]. 
Antimicrobial resistance (AMR) is the ability of a microorganism to withstand the effects 
of antimicrobials namely antiviral, antibiotic and antifungal medicines (AMR) with as a 
result AMR reduces the potential human health benefit derived from antibiotics and/or 
antiviral medicines [3]. A report from the World Health Organisation (WHO) has shown 
that 30% of bacteria were resistant to common antibiotics used to treat bacterial infectious 
diseases [4]. AMR is a serious burden, some bacteria and/or virus become so resistant 
that there is either only last resort antimicrobials or infections cannot be treated [5]. AMR 
is a leading cause of treatment failure and is largely responsible for the reduction in 
infectious disease extermination rates worldwide [6]. Infectious and non-infectious 
disease conditions are most of the time treated with antibiotics, which leads to the 
indiscriminate use of antimicrobials [7]. Virus and bacteria cause a large proportion of 
infectious diseases in Africa; bacterial infections account for 45% of deaths in Africa and 
South - East Asia [4] whereas 48% of premature deaths worldwide were caused by these 
infectious diseases [8]. Actually, due to antiretroviral therapy, the incidence of HIV 
infection has decreased from 0.40 per 1000 people non-infected with HIV/AIDS in 2005 
to 0.26 per 1000 people non-infected with HIV/AIDS worldwide in 2016 [9]. Similarly, 
from 2000 to 2016, the incidence of TB has decreased by 19 % over a 16-year period 
from 173 cases per 100 000 population to 140 per 100 000 population respectively. 
Despite the increase in the incidence of TB infection, drug-resistant TB remains a global 
menace; as a result among 600 000 registered new cases of TB resistant to rifampicin, 
there were 490 000 cases of multidrug-resistant [10]. 
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South Africa is no exception to widespread AMR; it confronts a triple AMR burden: drug-
resistant tuberculosis, drug-resistant HIV and antibiotic resistance [3]. People living with 
HIV / AIDS (PLWA) increased from 6.8 million in 2014 [11] to 7.52 million in 2018 
[12]. AMR is driven by many factors in South Africa, such as the careless use of 
prescribed antimicrobial medicines and the use of traditional medicine (TM), with the 
result that misadministration, interaction, and toxicity are always at risk [13].  
Traditional medicine (TM) was defined by the WHO as “the sum of knowledge, skills, 
and practices based on indigenous theories, beliefs and experiences of different cultures, 
whether or not explainable, used to maintain health and to prevent, diagnose, improve or 
treat physical and mental illness" [14]. Thus, plants are considered as one of the most 
promising sources for new antimicrobial medicines discovery; more than hundreds of 
plants in the world are used in TM for the treatment of viral and bacterial infections and 
other disease conditions by up to 80 percent of the population in Asia, Africa, Latin 
America, and the Middle East [15]. In the European Union, 100 million people believed 
also in the use of TM [16]. It is estimated that approximatively 27 million South Africans, 
including PLWA depend on TM for their primary health care needs [17]. This is relatively 
due to good accessibility to plants, affordability, and confidentiality of health information 
between patients and traditional health practitioners and the high cost of synthetic 
medicines [18]. Medicinal plants are also believed to combat the specific symptoms of 
diseases such as weight loss, skin disorders, lack of energy, digestive problems such as 
lack of appetite, diarrhoea, nausea, vomiting and treatment for side effects from 
antiretroviral medicines (ARVs) as well as dizziness, fungal infections, pain and stomach 
upsets [19, 20]. Studies from around the world have shown that people have used 
concurrently traditional medicine with different prescribed medicines. A study in North - 
East Scotland showed that women have the potential to increase the risk of postpartum 
hemorrhage, alter maternal hemodynamic and increase the depression of the central 
nervous system between mothers and fetuses [21]. In addition, another study showed that 
less than 20% of participants co-used TM and ARV; however, nearly 80% of participants 
use TM before contracting HIV infection [22]. Furthermore, 45% of study participants 
were co-users of conventional drugs and herbs, while a significant proportion of general 
health practitioners who co-used herbs with conventional drugs for their patients reported 
potential interactions or adverse effects due to the concomitant use of anticoagulants and 
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garlic [23]. TM is commonly used in combination with conventional medicines, mainly 
with satisfactory results, but in some cases, the effect of the two treatments can be 
increased, interacted and/or opposed [24]. Different patient groups are known to use 
herbal remedies and conventional drugs concomitantly (co-use). This poses a potential 
risk of interactions between herbal drugs by changing the pharmacokinetics or 
pharmacodynamics of the drug. Little is known about AMR among patients who co-use 
prescribed medicines antibiotic or antiviral medicines with TM. Individuals may consult 
both traditional healer (THPs) and biomedically trained healthcare professionals (BHPs) 
for bacterial and viral infections. However, there is a limited knowledge of interactions 
about the concurrent use of TM and prescribed medicines for bacterial and viral 
infections. This study aimed at determining whether any antimicrobial resistance and/or 
treatment failure could occur among patients attending out-patient departments (OPD) in 
selected healthcare facilities and who used concurrently traditional medicine with 
antibiotics and/or antiviral medicines in ILembe district, KwaZulu- Natal. 
Methods 
Study design 
This study was a cross-sectional descriptive study using medical chart review among 
patients attending OPD in two public healthcare facilities in the Ilembe district, KwaZulu-
Natal province, South Africa. 
 
   Study setting  
This study was carried out in ILembe district, one of the 11 districts of the province of 
KwaZulu-Natal in South Africa. ILembe is the smallest district municipality in the 
province with a surface area of 3,269 km2; it is approximately 75 km from Durban with 
a population of 630 464 inhabitants (90.8%), white population (2.4%t) and others (6.8%); 
the majority of the population in the district consists of native isiZulu speakers (82%) 
followed by native English speakers (9.6%), native Xhosa speakers (3.3%) and others 
(5.5%) [25].  It is located in KwaDukuza on the east coast of the province, bordering the 
Indian Ocean and comprises four municipalities: Mandeni, Ndwedwe, KwaDukuza, and 
Maphumulo. 
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There are four hospitals in the ILembe Health District namely: Montebello District 
Hospital, Stanger Provincial Hospital, Umphumulo District Hospital, and Untunjambili 
District Hospital. This study involved two hospitals: the Stanger Provincial Hospital in 
the municipality of KwaDukuza and the Umphumulo District Hospital in the municipality 
of Maphumulo. Both hospitals belong to the ILembe health department in the public 
sector.  
Fig. 4. 1 Map of the study area (http://www.kznhealth.gov.za/ilembe.htm). 
This map represents the area where data have been collected for this study. The map 
contains two different arrows that show the two hospitals (Hospital A and B) where the 
study were conducted. 
 Sample size calculation assumption 
Records or medical chart of patients aged 18 years and older were systematically sampled 
from January 2018 to March 2018. In general, a margin of precision of ±10%  requires a 
sample size of approximatively 100, which increases to approximatively 400 for a margin 
of precision of ±5%  and 10,000 for a margin of precision of ±1 %, for an expected 
prevalence of approximatively 50% for the outcome variable [26], the sample size was 
determined in respect of the calculation method [27] which stipulated that the sample size 
would be 377 for a sizeable population of 20,000 with a margin of precision of ±5 %, 
95% CI and within 50% as an equal distribution. Accordingly, Ilembe district has a 
population size of 630 464. The researcher assumed that the sample size for a large 
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population of 630 464 was at least 384 [28]. The study was oversampled by a maximum 
sample to include 400 medical chart reviews. 
Ethical approval  
Ethical approval to undertake the study was granted by the Biomedical Research Ethics 
Committee of UKZN (Reference BE476/17). In this phase of the study, no contacts were 
done with participants. Medical chart records were reviewed; findings of this study have 
been reported anonymously. No name, no personal identification and file numbers have 
been reported to protect the privacy and to maintain confidentiality about study 
participants. 
 
Recruitment process and selection of participants  
Medical chart records of adult patients, aged 18 years and above, irrespective of gender 
were selected at the OPD of the two selected healthcare facilities as well as at their 
respective TB and HIV clinics during clinic visit hours. Patients’ medical records from 
January 2017 to January 2018 were assessed and selected according to the study’s 
inclusion and exclusion criteria during the data collection period between February and 
March 2018. Records of patients who used concurrently TM and prescribed 
antimicrobials as well as who developed any side effects and/or interactions were 
reviewed in details.  
Data collection technique and instruments 
A medical chart review was conducted during four weeks between February and March 
2018. Data from four hundred (400) outpatients were collected manually by the researcher 
since there were no computerized records in the OPD. A data extraction form was 
specifically developed for the study. The form included the following information: 
patient’s address, age, gender, marital status, educational level, language spoken, 
occupation as well as viral infectious diseases, bacterial and/or fungal infectious diseases. 
Moreover, the details of any antimicrobials prescribed alone (antiretroviral, antibiotics 
and/or antifungals) or in association with other prescribed medicines, the use of 
traditional medicine, any adverse effects and interactions registered were assessed. The 
data extraction form was prepared in the English language. Thus, all the patient's 
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information needed for this study was recorded for every eligible out-patient in both 
hospitals.   
Statistical analysis 
Descriptive statistics using frequency and percentage were used to describe socio-
demographic characteristics of study participants. Data deriving from medical records 
using medical chart reviews were transferred into Excel spreadsheets, and then later 
analyzed using Statistical Package for Social Sciences (SPSS), software version 25. 
Categorical data were presented as tables. Prevalence of HIV infection, TB 
(Tuberculosis) infections, and other respiratory infectious disease were reported as a 
percentage with 95% confidence intervals (95% CI). Prevalence of use of traditional 
medicine and prescribed antimicrobials medicines were as well reported as a percentage 
with 95% CI. Associations between variables were carried out using Pearson Chi-Square 
tests. For multivariate analysis, a binary logistic regression analysis (adjusted odds ratio, 
AOR) was used. In addition, a separate multivariate logistic regression model was built 
to determine the association between use of TM and clinical outcomes.  A P-value ≤ 0.05 
was considered as statistically significant. Logistic regression analyses were used to 
calculate odds ratios for adverse effects and interactions regards to tradit ional medicine 
used. 
RESULTS 
This study reviewed 400 documented patients’ medical records in two different 
municipalities in Ilembe district, KwaZulu Natal, South Africa. 
1. Socio-demographic characteristics of study participants 
Table 1 presents the socio-demographic characteristics of the study participants. Overall, 
the majority of participants were black African (339/400, 84.80% [95%CI, 81-89]), 
female (218/400, 54.50% [95%CI, 50-60]), and unmarried (314/400, 78.50% [95%CI, 
74-82]). Most of the participants were employed (228/400, 57% [95%CI, 52-62]) and had 
attended at least primary school (174/400, 48.30% [95%CI, 43-53]). The median age was 
33 years old with a standard deviation of 16.42 (33 years old ± 16.42), range 18-93 years.  
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Table 4.1 Socio-demographic characteristics of participants 
Key: CI: Confidence Interval 
2. Prevalence of infectious diseases associated with HIV and TB among study 
participants 
Table 2 presents the prevalence of HIV, TB and other associated diseases or comorbidities 
among study participants. The majority of participants (194/400, 48.50% [95%CI, 43.6-
53.4]) had either HIV infection alone (49/194, 25.26% [95%CI, 19.15-31.37]) or a co-
infection of HIV and tuberculosis (61/194, 15.25% [95%CI, 10.19-20.31]) and finally 
HIV with other diseases (84/194, 43.30% [95%CI, 36.33-50.27]). Tuberculosis was 
documented either alone (35/49, 71.42% [95%CI, 58.77-84.07]) or in combination with 
other infections excluding HIV infection reported above (14/49, 28.57% [95%CI, 15.92-
41.22]). Overall, seventeen percent of participants had other respiratory infections 
excluding TB (67/400, 16.75% [95%CI, 13.03-20.41]). Besides HIV infection, TB either 
alone or associated with other comorbidities, other infectious diseases were documented 
in almost seven and a half percent (30/400, 7.50% [95%CI, 4.92-10.08]) while the 
Category Sub-category N (%) [95%CI] 
District ILembe Municipality A 200(50.0)[45-55] 
 Municipality B 
 Total 400(100) 
Gender Female 218(54.50)[50-60] 
Male 182(45.50)[41-51] 
 Total 400(100) 
 
 
Race 
Black African 339(84.75)[81-89] 
Indian 31(7.75)[5-10] 
(Mixed race) 18(4.50)[3-7] 
White 12(3.0)[2-5] 
 Total 400(100) 
Occupation Employed 228(57.0)[52-62] 
Unemployed 172(43.0)[38-48] 
 Total 400(100) 
 
Marital status 
Married 62(15.50)[12-20] 
Unmarried 314(78.50)[74-82] 
Widowed 24(6.0)[4-8] 
 Total 400(100) 
 
 
Educational level 
Illiterate 23(5.75)[4-8] 
Primary School 193(48.25)[43-53] 
Secondary School 174(43.50)[39-49] 
Tertiary 10(2.5)[1-4] 
 Total 400(100) 
 
 
Language spoken 
English & Afrikaans 43(10.75)[8-14] 
IsiZulu 340(85.0)[81-88] 
IsiZulu & English 17(4.25)[2-6] 
 Total 400(100) 
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remainder of participants had non-communicable diseases (63/400, 15.75% [95%CI, 
12.18-19.32]).  
Table 4.2 Frequency of communicable and non-communicable infectious diseases associated to 
HIV and Tuberculosis 
Key: AOR: Adjusted odds ratio that is obtained from binary logistic regression, CI:  confidence interval,   HIV: human 
immunodeficiency virus 
 
 
 
Category Sub-category Frequency documented 
diseases (%) 
P value, AOR (95% 
CI) 
 
 
 
HIV 
infection 
 
 
HIV infection alone 49(12.25)  
 
 
P ˂ 0.001 
0.073(0.039-0.14) 
HIV with Tuberculosis 61(15.25) 
HIV with other bacterial infectious diseases 
(Pneumonia (3), meningitis (2) and other (12) 
21(5.25) 
HIV with Fungal infectious diseases non-identified 6(1.5) 
HIV with other Sexually Transmitted Diseases (10) and 
three viral infectious diseases (shingles(1), genital 
warts (2) 
13(3.25) 
HIV with Non communicable diseases (Hypertension 
(6), Assault (injury) (5), renal failure (5) and other (28) 
44(11) 
Subtotal 194  
 
 
 
Tuberculosis 
infection 
 
 
Tuberculosis infection alone  35 8.75(6.1 – 11.4) 
Tuberculosis with other Bacterial infectious 
diseases(Pneumonia (3), Meningitis(2)), one fungal 
infection (candidiasis) and one viral infectious 
disease(Hepatitis B) and with two others 
9 
 
2.25(0.88 – 3.62) 
 
Tuberculosis with non-communicable diseases 
(Gastroenteritis acute (2), asthma (1) and two others 
diseases 
5 1.25(0.27 – 2.23) 
Subtotal 49  
 
 
 
 
 
Respiratory 
infection 
 
 
Respiratory infections alone (Pneumonia (3), Upper 
respiratory tract infection (3), Pharyngitis (2) and other 
(6)) 
14 3.5(1.83 – 5.17) 
Respiratory infection with other infectious diseases: 
Pneumonia with lower respiratory     tract infection (1), 
Upper respiratory tract infection with diarrhea(1) 
,Upper respiratory tract infection with Tinea pedis (1) 
and Other  diseases (4) 
 
 
7 
1.75 (0.79 - 2.71) 
Respiratory infection with non-communicable 
diseases(Lower respiratory tract infection with Acute 
gastroenteritis (4), Pneumonia with Asthma (4) and 
other diseases (35)  
43 10.75(7.69 – 13.81) 
Subtotal 64  
Other infectious diseases alone (Urinary tract infection (3), one herpes 
simplex and other infectious diseases alone (26) 
30 7.5(5.01 – 9.99) 
Non-communicable diseases (Hypertension (11), Diabetes (5) and 
other diseases (47) 
63 15.75(12.26 – 19.24) 
Total 400 100% 
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3. Documented   medicines prescribed (antimicrobial and non-antimicrobials) by 
BHPs 
Table 3 presents the frequency of documented antimicrobial medicines prescribed by 
biomedically trained healthcare professionals. Most of the medical records reviewed for 
study participants contained prescribed antimicrobials (356/400, 89.0% [95%CI, 85.93-
92.07]) while the remainder had other prescribed medicines than antimicrobials 44/400, 
11.0% [95%CI, 7.93-14.07]).  
Overall, 1497 medicines were identified within study participants’ medical chart records. 
Although the majority of medical records contained infectious diseases and the 
appropriate antimicrobial treatment; non-antimicrobial medicines (808/1497, 53.97% 
[95%CI, 51.45-56.49]) were predominantly prescribed in conjunction with antimicrobials 
(689/1497, 46.03% [95%CI, 43.51-48.55]). Those non-antimicrobials consisted mainly 
of Paracetamol in combination with other painkillers (Paracetamol +Codeine + Potassium 
sorbate), which accounted for at least sixteen percent (131/808, 16.21% [95%CI, 13.67-
18.75]). Antimicrobial medicines were mainly common antibiotics or antifungals 
(389/689, 56% [95%CI, 52.29-59.71]) such as Augmentin® (Amoxicillin + Clavulanate), 
or Bactrim® (Sulfamethoxazole + Trimethoprim), Flagyl® (Metronidazole), and 
Fluconazole. They were followed by antiretroviral medicines (190/689, 27.58% [95%CI, 
24.24-30.92]) in a fixed-dose combination antiretroviral containing either Tenofovir + 
Emtricitabine + Efavirenz or Abacavir + Lamivudine + Lopinavir; and finally followed 
by anti-tuberculosis medicines (110/689, 15.97% [95%CI, 13.23-18.71]) consisting of a 
fixed dose combination Rifafour® made of Rifampicin + Ethambutol + Isoniazid + 
Pyrazinamide.  
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Table 4.3 Documented   medicines prescribed (antimicrobial and non-antimicrobials) by BHPs 
 
               Frequency of participants (N=400, %)  Frequency of prescribed medicines used N=1497, (%) 
 
 
Prescribed antiretroviral 
Fixed dose combination 
(FDC) 
Tenofovir + Emtracitabine 
+ Efavirenz or Abacavir + 
Lamivudine + Lopinavir)  
FDC (alone)  31(7.75) FDC (alone)  31(2.07) 
FDC with Rifafour® consisting of a fixed dose combination 
(Rifampicin + Ethambutol + Isoniazid + Pyrazinamide ) 
31(7.75) FDC(31) with Rifafour® consisting of a fixed dose 
combination (Rifampicin + Ethambutol + Isoniazid + 
Pyrazinamide )(31) 
62(4.14) 
FDC with other prescribed antibiotics(Augmentin 
(amoxicillin + Clavulanate) (9) and to other medicines (74)  
83(20.75) FDC(83) with other prescribed antibiotics(Augmentin 
(amoxicillin + Clavulanate) (9) and to other medicines(74)  
166(11.08) 
FDC with prescribed antifungals(Cotrimazole(3), prescribed 
antibiotics and other prescribed medicines(23) 
26(6.5) FDC(26) with prescribed antifungals(Cotrimazole(3), 
prescribed antibiotics and other prescribed medicines(23) 
75(5.01) 
FDC with other prescribed medicines(Amlodipine(3), 
Hydrochlorothiazide(2) and other (14) 
19(4.75) FDC with other prescribed medicines(Amlodipine(3), 
Hydrochlorothiazide(2) and other (14) 
38(2.53) 
Other antiviral used(Acyclovir) associated to 8 other prescribed medicines 4(1) Other antiviral used(Acyclovir) associated to 8 other 
prescribed medicines 
12(0.80) 
Subtotal 194(48.5)  384(25.62) 
 
 
 
 
Prescribed antibiotics  
Rifafour (Rifampicin +Ethambutol+ Isoniazid + 
Pyrazinamide ) with other prescribed antibiotics(Augmentin 
(amoxicillin + Clavulanate)(10), Bactrim(sulfamethoxazole 
+ trimethoprim )(8) and others(61) 
79(19.75) Rifafour (Rifampicin +Ethambutol+ Isoniazid + 
Pyrazinamide ) with other prescribed antibiotics(Augmentin 
(amoxicillin + Clavulanate)(10), Bactrim(sulfamethoxazole 
+ trimethoprim )(8) and others(61) 
158(10.55) 
Other prescribed antibiotics used alone Flagyl 
(Metronidazole)(4), Praziquantel (2) and other (13) 
19(4.75) Other prescribed antibiotics used alone Flagyl 
(Metronidazole)(4), Praziquantel (2) and other (13) 
19(1.27) 
Other combination between prescribed 
antibiotics(Amoxicillin with metronidazole(8), 
Clotrimazole with Fluconazole (4) and other (52)  
64(16.0) Other combination between prescribed 
antibiotics(Amoxicillin with metronidazole(8), 
Clotrimazole with Fluconazole (4) and other (52)  
128(8.55) 
Subtotal 162(40.5)  305(20.37) 
Other prescribed medicines (Panado: Paracetamol +Codeine + Potassium sorbate)(131), 
Pyridoxine(113), Multivitamin (49), Brufen (Ibuprofen(43) and other (472) 
44(11) Other prescribed medicines (Panado: Paracetamol +Codeine 
+ Potassium sorbate)(131), Pyridoxine(113), Multivitamin 
(49), Brufen (Ibuprofen(43) and other (472) 
808(53.97) 
Total 400(100)  1497(100) 
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4. Documented clinical outcomes of the  concurrent use of TM and prescribed 
medicines among study participants  
Table 4 presents the documented concurrent use of TM and prescribed medicines among 
study participants. Overall very few participants (15/400, 3.75% [95%CI, 1.89-5.61]) 
used TM with their prescribed medicines whose clinical outcomes were also documented 
in their medical chart records. Eight out of fifteen documented cases (8/15, 53.33% 
[95%CI, 28.08-78.58]) consisted mainly of treatment failure and drug resistance to the 
first line ARV treatment and a persistent rash to conventional treatment, loss of scrotum 
pigmentation, diarrhea, nausea, vomiting, body pain, headache, and renal impairment. 
Twelve cases (12/33, 36.36% [95%CI, 19.95-52.77]) were documented having drug 
resistance and treatment failure either from the first line or the second line of 
antiretroviral therapy,  severe renal impairment, rashes, kidney pain, jaundice, painful 
lower limbs, weakness, and vomiting. 
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Table 4. 4 Documented clinical outcomes of the concurrent use of TM and prescribed medicines  
Use of TM (N=15) 
 
Non-use of TM(N= 385) 
Conditions Prescribed medicines used Documented 
interactions 
Documented 
adverse effects 
Conditions Prescribed medicines used Documented 
interactions 
Documented adverse 
effects 
HIV infection 
disease 
FDC, Aminophylline, Bactrim 
(Cotrimoxazole or 
sulfamethoxazole + 
trimethoprim), 
Panado(Paracetamol +Codeine + 
Potassium sorbate)   
Herbal intoxication(1), 
Treatment failure(to the 
first line) 
Unconsciousness 
due to overdose (1), 
Nausea(1) and 
headache(1) 
HIV infection alone FDC, Bactrim (Cotrimoxazole 
or sulfamethoxazole + 
trimethoprim), Fluconazole, 
Clotrimazole, Multivitamin 
Drug resistance and 
treatment failure(7) 
either of the first line 
or the second line of 
FDC  
Missed of period(1),  
Shingles, and 
sores(1), Genital 
warts(1), vomiting(2), 
Dizziness(2), Loss of 
balance, 
Headache(1), 
Weakness(1), 
Stomach cramps  
HIV with TB 
and/or other 
disease 
FDC, Rifafour(Rifampicin + 
Ethambutol + Isoniazid + 
Pyrazinamide), Bactrim 
(Cotrimoxazole or 
sulfamethoxazole + 
trimethoprim), Augmentin 
(Amoxicillin + Clavulanate 
potassium), Multivitamin, 
Fluconazole, Verofer( 
Iron sucrose) 
, Rocephin (Ceftriaxon), 
Azythromycin, 
Clexane(Enoxaparin) 
, FeSO4, Paracold(Paracetamol + 
Codeine phosphate), Voltaren( 
Diclofenac Sodium) 
, Betamethasone, 
Brufen(Ibuprofen), Allergex, 
Sorol Citrate, Ampicillin, 
Prednisolone, Clotrimazole cream, 
Flucox(Flucloxacillin), Aciclovir   
Herbal intoxication (1), 
Treatment failure(3) and  
Drug resistance (to the 
first line ARV 
regimen)(1), and 
persistent  Rashes to 
conventional treatment 
Loss of scrotum 
pigmentation(1), 
Diarrhea(2), Rash 
resistant(2), 
Nausea(1), 
Diarrhea(1), body 
pain(1), 
Headache(1), 
Rashes, Renal 
impairment(2) 
HIV with 
Tuberculosis 
infection 
FDC, Rifafour(Rifampicin + 
Ethambutol + Isoniazid + 
Pyrazinamide), Augmentin 
(Amoxicillin + Clavulanate 
potassium), Bactrim 
Cotrimoxazole or 
sulfamethoxazole + 
trimethoprim),, Norfloxacin, 
Pyridoxine, 
Panado(Paracetamol +Codeine 
+ Potassium sorbate), Dapsone, 
Multivitamin, Vitamin BCo, 
Vitamain C 
Drug resistance(2) 
and treatment 
failure(1) either of the 
first line or the second 
line of FDC 
Severe renal 
impairment(2), 
Rashes(1), Kidney 
pain(2), Jaundice 
bloods(1), Painful 
lower lmbs(1), 
Weakness(1) , 
Diarrhea (1) and 
Vomitting(2) 
Tuberculosis 
infection alone 
Rifafour(Rifampicin + 
Ethambutol + Isoniazid + 
Pyrazinamide), Pyridoxin, 
None None HIV with Mouth 
ulcer and other 
diseases 
FDC, Bactrim Cotrimoxazole or 
sulfamethoxazole + 
trimethoprim),, Flucloxacillin, 
Flagyl(Metronidazole), 
Drug resistance(1) 
and treatment failure 
either of the first line 
Diarrhea(1), 
Vomitting (1)  and 
Kidney failure (1) 
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Panado(Paracetamol +Codeine + 
Potassium sorbate), Multivitamin 
Lansoloc(Lansoprazole), 
Brufen(Ibuprofen), Buscopan 
(hyoscine butylbromide), 
Fluconazole, Clotrimazole 
or the second line of 
FDC 
Abdominal 
pain(Renal 
impairment) 
Buscopan (hyoscine 
butylbromide) 
and ringer lactate 
Herbal intoxication(1) Abdominal pain(1), 
vomitting(1), body 
weakness(1) 
TB with AGE Rifafour(Rifampicin + 
Ethambutol + Isoniazid + 
Pyrazinamide), 
Augmentin(Amoxicillin + 
Clavulanate potassium), 
Rocephin(Ceftriaxone), 
Clotrimazole, Nystatin, 
Maxolon (metoclopramide), 
Sorol Citrate, Allergex, 
Pyridoxine, 
Panado(Paracetamol +Codeine 
+ Potassium sorbate), 
Multivitamin 
None Vomitting and 
abdominal pain(2) 
Gastritis and 
Septisis 
Augmentin (Amoxicillin + 
Clavulanate potassium), Rocephin 
(Ceftriaxone), 
Flagyl(Metronidazole), 
Maxolon(Metoclopramide)  
, Lansoprazol 
None Vomitting and 
weakness 
TB with Pneumonia Rifafour(Rifampicin + 
Ethambutol + Isoniazid + 
Pyrazinamide), 
Augmentin(Amoxicillin + 
Clavulanate potassium), 
Azythromycin, 
Rocephin(Ceftriaxone), 
Pyridoxine, 
Panado(Paracetamol +Codeine 
+ Potassium sorbate), Vit C 
None Loss of energy and 
Headache 
Key: ARV: antiretroviral medicines, FDC: Fixed dose combination, TM: traditional medicine, HIV: human immunodeficiency virus, TB: tuberculosis.   
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5. Association between the use of traditional medicine and documented adverse 
effects and interactions. 
Table 5 presents an association between the use of TM and adverse effects and/or 
interactions. Overall, less than ten percent of patients had documented adverse effects 
(7.5%, 30/400 [95%CI, 4.92-10.08]). A small percentage of participants (15/400, 3.75% 
[95%CI, 1.89-5.61]) have reportedly used TM, only twelve out of fifteen (12/15, 80% 
[95%CI, 59.76-100.24]) had adverse effects due to the use of TM (Renal impairment, 
diarrhea, vomiting, abdominal pain, and weakness), 4.5% of patients had reported 
interactions (18/400, [95%CI, 2.47-6.53]); seven out of eighteen had reportedly used TM 
(38.89% (intoxication and treatment failure), while seven out of fifteen (7/15, 46.67% 
[95%CI, 21.42-71.92]) of documented interactions were related to the use of traditional 
medicine (7/15). Of those 15 participants, 60% were female (9/15, [95%CI, 35.21-
84.79]), 73.33% had attended at least primary school (11/15, [95%CI, 50.95-95.71]), and 
were employed (12/15, 80% [95%CI, 59.76-100.24]). 
Documented interactions and adverse effects were significantly associated with the use 
of TM in combination with prescribed medicines using Pearson Chi-square (p< 0.001). 
Using multiple logistic regression models, the risk estimate of using of TM alongside 
with prescribed medicines was higher among females gender compared to males (AOR= 
0.93; 95%CI [0.34-2.54]). After adjustment, documented adverse effects and interactions 
were significantly more likely to the use of traditional medicine (AOR = 0.01, 95% CI 
[0.001-0.05]) and (AOR = 0.21, 95% CI [0.37-1.23]), respectively.  
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Table 4.5 Association between the use of traditional medicine and documented adverse effects 
and interactions. 
 Key: AOR: Adjusted odds ratio that is obtained from binary logistic regression, TM: traditional medicine
 
Variables (N=400) 
Use of TM (N=15) P-Value 
(χ2) 
AOR (95% CI) 
No Yes  Total 
Gender Female 209 (52.25%) 9 (2.25%) 218 (54.50%)  
P=0.886  
 
1.07(0.3-2.9) 
Male (Ref.) 176 (44%) 6 (1.50%) 182 (45.50%) 
Educational 
Level 
Illiterate 23 (5.75%) 0 23 (5.75%)  
P=0.199 
 
 
0.2(0.02-2.1) Primary Sc. 182 (45.50%) 11 (2.75%) 193 (48.25%) 
Secondary Sc. 170 (42.50%) 4 (1.00%) 174 (43.50%) 
Tertiary (Ref.) 9 (2.25%) 1 (0.25%) 10 (2.50%) 
Documented 
Adverse effects 
No  367 (91.75%) 3 (0.75%) 370 (92.50%) P=0.000 
 
0.01(0.001-0.05)* 
Yes (Ref.) 18 (4.50%) 12 (3.00%) 30 (7.50%) 
Documented 
Interactions 
No 374 (93.50) 8 (2.00%) 382 (95.50%) P=0.000 
 
0.21(0.37-1.23)* 
Yes (Ref.) 11 (2.75%) 7 (1.75%) 18 (4.50%) 
 Total 400   
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Discussion 
This study aimed at determining whether any antimicrobial resistance and/or treatment 
failure occurred among patients who used concurrently traditional medicine with 
antibiotics and/or antiviral medicines, and attending out-patient departments in selected 
healthcare facilities in ILembe district, KwaZulu- Natal. 
This study found that a few participants had a documented concurrent use of TM with 
prescribed medicines (15/400, 3.75%). Traditional medicine was not commonly used by 
the study participants 385/400 (96.25%) as showed in Table 5. This finding is in 
agreement with another study carried out in eThekwini municipality [29] which showed 
a quite low use of  ARV in conjunction with TM (4.98%). A study done by Hughes et al., 
(2012) revealed that less than 20% of participants co-used TM and ARV [22, 30].  
However other studies done in Nigeria [31] and in North-East Scotland [21] indicated in 
contrast a high prevalence (69.4% and 44.9% respectively) of the concurrent use of both 
TM and prescribed medicines. According to the WHO [32], this trend may be attributed 
to accessibility, affordability, and availability of traditional medicines in the world. 
In this study, there was no statistically significant association between use of TM and 
gender (P value=0.886) and level of education (P value=0.199). The majority of those 
who used TM were female participants (9/15, 60%). This was in agreement with other 
studies carried out in Iraq [33] and in Nigeria [34] which stated that 52.9% and 72.4% 
respectively of female participants used more TM concurrently with their prescribed 
medicines than males. The preponderance of female proportion in this study (9/15) was 
similar to other studies that reported that female gender was a predictor of traditional 
medicine use amongst people living with AIDS [22, 35]. 
This study found a few cases of documented adverse effects (30/400) and interactions 
(18/400) as clinical outcomes; among those who had adverse effects, 40% (12/30) used 
concurrently TM while 38.89% (7/18) had interactions and used concurrently TM. After 
adjustment in this study, documented adverse effects and interactions were significantly 
more likely to the use of traditional medicine (AOR = 0.01, 95% CI = 0.001-0.05) and 
(AOR = 0.21, 95% CI = 0.37-1.23) respectively. These results were in agreement with  
similar studies conducted in Norway [23] which showed that patients who used 
concurrently conventional medicines with TM, had significantly (p < 0.05) increased 
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odds of having experienced adverse effects (AOR 37.5); in the same way McLay et al., 
[21] showed that  pregnant women who co-used TM and conventional medicines had 
postpartum hemorrhage and altered maternal hemodynamic. Interactions between TM 
and prescribed medicines can occur and may lead to negative clinical consequences. 
However, the results of this study were in contradiction with other studies carried out in 
Portugal and around the world which showed that antimicrobial compounds from plants 
have revealed to be synergistic enhancers in that though they may not possess any 
antimicrobial properties alone, but when used concurrently with prescribed medicines 
they enhance the activity of the medicine and co-users of both TM and prescribed 
medicine feel quality of life improved [36, 37] . 
This study found a high prevalence of HIV infection (47.5%, 190/400). This finding is in 
agreement with a published report on the high prevalence of HIV infection in KwaZulu-
Natal as well as the most prevalent province (Approximatively 26.6 %) among the top 
four high HIV-prevalent provinces [12]. Shah et al. [38] showed in their report that of 
404 participants, 311 (77%) had HIV infection in KwaZulu Natal. The South African 
government has highlighted earlier that aspects of poverty in townships such as 
inadequate sanitation and food, unemployment and poor education, violence, and crime 
have been associated with increased HIV transmission [39].  
Strengths and limitations of the study 
This phase of the study was a medical chart review; no direct contacts were made with 
patients reportedly using concurrently TM and prescribed medicines. Some more 
information could have been collected by talking directly to patients themselves. The 
findings of this study should be interpreted with caution. They cannot be generalized to 
the entire province of KwaZulu-Natal and to South Africa. Further studies are needed in 
other districts of KwaZulu-Natal and the rest of South Africa. There was a difficulty of 
finding data that revealed the type of TM used since documented patient medical records 
do not highlight it properly.  In addition, studies involving direct interactions with 
patients, BHPs and THPs are warranted to gather more information on the problem under 
study. 
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Conclusion 
The findings from the present study revealed a low documented use of traditional 
medicine in conjunction with prescribed antibiotic and/or antiviral medicines. Patients 
had a high prevalence of viral infections (with emphasis on HIV infection) and bacterial 
infections (with emphasis on tuberculosis infection and other respiratory infectious 
diseases). Few documented adverse effects and interactions were documented among 
those who used concurrently TM and prescribed medicines in the healthcare facilities 
included in this study. Further studies are needed to investigate the effects of concurrent 
use of TM and prescribed medicines on antimicrobial resistance and/or treatment failure 
in other parts of South Africa. 
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CHAPTER 5: SYNTHESIS CHAPTER 
 
5.1 Synthesis and discussion – Significance of major findings 
This chapter highlights the major findings of this study, it gives a general conclusion 
drawn from the study and provides recommendations for future investigations.  
5.1.1 Perceptions from THPs, patients seen by them, BHPs and outpatients about the 
concurrent use of traditional medicines and prescribed antimicrobial medicines for 
infectious diseases 
The phase one of this study was a qualitative study using a face to face interview with four (4) 
types of participants namely: THPs, patients seen by THPs, BHPs and outpatients.  
i. This study found a small number of medicinal plants used by THPs such as Spirostachys 
Africana sond (Umtombothi), Hypoxis hemerocallidea (magic muthi or inkofe) and 
Sutherlandia frutescens (Insiswa or Unwele) for infectious diseases. A similar study 
conducted in Mpoza, South Africa reported that among seventeen plant species identified for 
the management of HIV and other related infectious diseases, Hypoxis hemerocallidea (85%) 
was the most frequently used medicinal plants (Gail et al., 2015); in the same line, another 
study reported that  Hypoxis hemerocallidea and Plectranthus amboinicus were the herbal 
medicines used not only for boosting the immunity but also in the management of HIV 
infection and  bacterial infections (Maroyi, 2014). 
In this study the majority of THPs could not reveal the specific recipe used for each disease 
condition treated with the listed plants above; a few THPs indicated that they used 
Sutherlandia frutescens for “boosting the immune system.” THPs in this study also used 
Hypoxis hemerocallidea and Sclerocarya birrea (Umganu) for treating diarrhea (Isifo 
sohudo) and HIV infection (Igciwane lengculazi). Similarly, another study in Namibia 
reported that medicinal plants and other recipes used to manage HIV infection and other 
opportunistic infectious diseases were not disclosed by THPs at all because they were values 
and indigenous knowledge; THPs preferred to keep this knowledge as a secret for themselves 
(Chinsembu et al., 2015). 
 
ii. This study found that 65.62% of THPs and their patients (21/32) mixed different herbs for 
the treatment of infectious diseases; moreover, respondents in this study agreed that when 
combining both TM and prescribed medicines for infectious diseases, interactions and 
adverse effects may result and if there is no respect of time lapses between the two medicines, 
  
88 
 
the infectious disease may get worse. For supporting these findings, synergistic and 
antagonistic interactions were noted among six Southern African medicinal plants when 
associated with seven prescribed antimicrobial medicines in a study conducted in South 
Africa (Hübsch et al., 2014). Medicinal plants may contain multiple ingredients and when 
used simultaneously with prescribed medicines, either therapeutic effects may occur or side 
effects and treatment failure may also happen. In contrast, a very little attention was given to 
the safety of TM because only a small number of interactions  between TM and conventional 
medicines were found by the Brazilian Unified Public Health System (Mazzari and Prieto, 
2014); in the same line, a study conducted in the East Asian part concluded that the use of 
TM can be associated with prescribed medicines but this depends to the medical systems of 
each country (Shim, 2016). 
 
iii. Outpatients (30%, 15/50) in this study reported that TM can fight infectious diseases if using 
the right dose and the right medicinal plant; in addition, they responded that TM if associated 
with prescribed medicines could fight completely infectious diseases and then some of them 
(20/50, 40%) reported that they stopped with using TM when started with prescribed medicine 
or when they knew their HIV status because BHPs would not allow the use of both. Another 
study reported that TM could fight infectious diseases such as symptoms of HIV infection, 
tuberculosis, diarrhoea, skin rashes and other opportunistic infections. The frequent plant 
parts used were leaves, fruits and seeds mainly through oral administration (Gurrapu and 
Mamidala, 2016). Perspectives from respondents in this study were supported by a study done 
in Mozambique which reported that the majority of PLWA (62%) went to see first their THPs 
for only some strange symptoms status; secondly, without knowing their HIV status, they just 
join the clinic only when the symptoms persist (Audet et al., 2014). The delay in diagnosis 
and treatment of HIV infection is registered when there is no early referral from THPs to 
BHPs. However the use of TM is hardly reported by patients to BHPs ; a study done in Kenya 
reported that only 12.5 % of pregnant women revealed to their BHPs the use of TM alone or 
in association with prescribed medicine for same disease conditions (Mothupi, 2014). 
Respondents in this study including BHPs and outpatients reported that combining TM and 
prescribed medicines for infectious diseases may result in drug resistance especially 
resistance to antibiotics and they highlighted that the majority of patients came to the clinic 
with several complications such as kidneys failure, vomiting, diarrhea and jaundice after 
using either TM alone or in combination with prescribed medicines. A study agreed that 
medicinal plants contain different compounds in one mixture that constitute a challenge 
regards to side effects and interactions with enzymes of medicines metabolism when they 
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are used in conjunction with prescribed medicines (Thomford et al., 2015). In addition, a 
clinical study conducted in USA, found that PLWA combined TM treatment to ARVs and 
developed side effects such as viral resistance and inhibition of medicines metabolism that 
lead to toxicity. Many medicinal plants are able in their mechanism of action to inhibit the 
action of enzymes of medicines metabolism; thus it would be necessary for BHPs, THPs and 
patients to be aware of interactions and side effects per avoiding the consumption at the same 
time of TM and ART (Fasinu et al., 2016). From these experiences stated by respondents in 
this study, concurrent use of conventional medicines and TM at the same time may interfere 
or may result in damaging of some organs, failure of the treatment as well as modifying drugs 
pharmacological action.  
5.1.2 Clinical outcomes from a medical chart review following the concurrent use of 
prescribed antimicrobial and traditional medicines 
This second phase of the study was a quantitative approach using a medical chart review of 
outpatients attended Stanger hospital and Umphumulo hospital and who used concurrently TM 
and prescribed medicines for their infectious diseases conditions. 
 
i. Traditional medicine was not commonly documented in medical chart records of study 
participants. This study found that a few participants had a documented concurrent use of TM 
with prescribed medicines (15/400, 3.75%). A similar study reported a small number of 
participants (20%) that co-used TM with prescribed antimicrobial medicines for their 
infectious diseases (Abou-Rizk et al., 2016). Furthermore,  another study done in Kenya by 
Mothupi (2014) reported that  12.5% of pregnant women disclosed the use of TM to their 
BHPs, and only 20% used TM at the same time with prescribed medicines for their disease 
conditions such as malaria, respiratory tract infections and other infectious diseases;  while 
serious adverse effects were noted in a study conducted by Izzo et al(2016) among pregnant 
women who used TM for cystitis prevention, nausea, hypertension, migraine and other 
conditions, although clinical results for side events showed that TM was more tolerated by 
pregnant women than conventional medicines (Mothupi, 2014; Izzo et al., 2016). However, 
a study done in Nigeria had reported in contrast a high rate (69.4%) of concomitant use of 
TM and prescribed medicines for disease  conditions  such as malaria, typhoid fever and other 
(MO, 2009). 
ii. This study found a few cases of documented adverse effects (30/400) and interactions 
(18/400) as clinical outcomes; among those who had adverse effects, 40% (12/30) used 
concurrently TM while 38.89% (7/18) had interactions and used concurrently TM. This was 
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supported by a study that showed the production of an antagonistic effect against P. 
mirabilis and E. faecalis when medicinal plants associated with prescribed antimicrobial 
medicines while a synergistic effect was produced against P. aeruginosa (Ofokansi et al., 
2013).  In addition, a clinical case report study showed potential interaction on HIV infected 
women who used concurrently TM and ARVs; the most developed adverse effects were liver 
injury and jaundice (Mateo-Carrasco, 2013). Documented adverse effects and interactions 
were significantly more likely to the use of traditional medicine after adjustment (AOR = 
0.01, 95% CI = 0.001-0.05) and (AOR = 0.21, 95% CI = 0.37-1.23) respectively.  In contrast, 
Darwish and Aburjai (2010) reported in their findings a possibility of combining prescribed 
antibiotics with medicinal plants for managing infectious diseases caused by E. coli. In the 
same line, Shim (2016) reported the promote of the East Asian medicines on the concomitant 
use of TM with prescribed medicines but this depends to the medical systems of each country 
(Shim, 2016). 
5. 2 General Conclusions drawn from the study findings  
This study was conducted in the ILembe district, KwaZulu-Natal province, South Africa and 
aimed to investigate whether antimicrobial resistance or treatment failure could occur among 
patients attending out-patient department of selected healthcare facilities, who used concurrently 
traditional medicine and prescribed antimicrobial medicines. 
 In this study, a mixed approach method was used which firstly included face to face interviews 
with THPs and patients seen by them; thereafter interviews were conducted with BHPs, and lastly 
with outpatients seen by both THPs and BHPs attending the outpatient department in the two 
selected healthcare facilities namely Stanger Hospital and Umphumulo Hospital. Secondly, Phase 
two consisted of a medical chart review of outpatients who came from THPs and files of those 
other outpatients who used concurrently TM and prescribed antimicrobial medicines.  
This study demonstrated different perceptions from THPs, BHPs and their treated patients with 
medicinal plants used concurrently with prescribed antimicrobial medicines and their effects on 
antimicrobial resistance and treatment failure. A small number of medicinal plants were reported 
with antibacterial and antiviral properties. THPs and their patients confirmed that they have 
combined medicinal plants for a positive result. Cases of interactions and adverse effects were 
referred by THPs to the nearest hospital. However, 40 percent of the interviewed outpatients 
(20/50) in this study confirmed that they stopped with TM when they started with prescribed 
antimicrobial medicines. The majority of BHPs reported that adverse effects such as kidney 
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failure, vomiting, diarrhoea and jaundice were the most common clinical outcomes among 
patients who used either TM alone or in combination with prescribed medicines.  
Besides perceptions from participants, the findings from the present study revealed as well a low 
documented use of traditional medicine in conjunction with prescribed antibiotic and/or antiviral 
medicines. Patients had a high prevalence of viral infections (with emphasis on HIV infection) 
and bacterial infections (with emphasis on tuberculosis infection and other respiratory infectious 
diseases). Few documented adverse effects and interactions were documented among those who 
used concurrently TM and prescribed medicines in the healthcare facilities included in this study. 
Documented interactions and adverse effects were significantly associated with the use of TM in 
combination with prescribed medicines using Pearson Chi-square (p< 0.001). Using multiple 
logistic regression models, the risk estimate of using of TM alongside with prescribed medicines 
was higher among females gender compared to males (AOR= 0.93; 95%CI [0.34- 2.54]). After 
adjustment, documented adverse effects and interactions were significantly more likely to the use 
of traditional medicine (AOR = 0.01, 95% CI [0.001-0.05]) and (AOR = 0.21, 95% CI [0.37-
1.23]), respectively. 
Strengths and limitations of the study  
This was a mixed method approach study using both qualitative and quantitative as study design. 
This study was a triangulation study including four (4) types of participants, namely THPs, 
patients seen by THPs, BHPs and outpatients. This study had its strength when revealing that the 
use of both TM and prescribed antimicrobial medicines for patients who had bacterial, viral and/or 
fungal infections developed adverse effects and interactions. 
This study had a few limitations. This was a survey in its first phase with self-reports collected 
from respondents. There was neither observation of THPs in their practices nor experimentations 
conducted by researchers. Among outpatients, there were very few cases referred by BHPs for 
the concurrent use of prescribed antimicrobial and traditional medicines. Although this study 
matched information from THPs and a few patients seen by them, there was no documented 
evidences about self-reports received either by THPs or patients seen by them. The concurrent 
use of TM and prescribed antimicrobial medicines was under-reported by participants because of 
embarrassment or belief that their medical providers were against TM use or their information 
could be divulgated  (Puoane et al., 2012). The majority of medicinal plants used by THPs for 
infectious diseases or other disease conditions were not reported by them and kept as secret. There 
was also a limitation of finding documented patients’ medical records that revealed the type of 
TM used, since documented patient medical records do not highlight it properly in the phase two. 
However, this results should be interpreted with caution and cannot be generalized to the entire 
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population of THPs, patients seen by them, BHPs and outpatients in the entire province of 
KwaZulu-Natal and South Africa.  
5.3 Recommendations 
Results from this study are of benefit to researchers by highlighting gaps in evidence that may 
need further investigation. Further studies are needed in other parts of South Africa to investigate 
the effects of concurrent use of traditional medicine and prescribed antimicrobial medicines and 
to implement any bidirectional referral between THPs and BHPs in the reduction of any 
interactions and adverse effects occurring when patients use both TM and prescribed 
antimicrobial medicines. In addition, experimental studies can also be run by using those 
medicinal plants used in combination with prescribed medicines. Future experimental and well-
designed studies would be beneficial in terms of outcomes and in the perspective of counselling 
or advising the two parties involved (THPs and BHPs) on the change in their respective practices 
for the improvement of the health of patients using both traditional and western medicines. 
Bidirectional referral between THPs and BHPs and an implementation or creation of medical 
records for patients seen by THPs will be required for the documentation of their information. 
Further studies are also needed to depict intrinsic and extrinsic factors contributing to the success 
or failure of treatment. Bidirectional referral between THPs and BHPs and an implementation or 
creation of medical records for patients seen by THPs will be required for the documentation of 
their information. 
 
With a view of conceptualizing the conditions for collaboration between the two systems, an 
earlier concept was suggested by Pretorius (Pretorius, 1991) in which he proposed the analogical 
model of the Biomedical/Traditional Medical Relationship, this model shows clearly that each 
aspect of the traditional medicine system may be linked to the western medicine system such as 
mutual referral. In addition, the WHO has adopted the strategies to ensure the integration of 
collaboration between  research institutions and THPs based on research and management of 
patients; and between THPs and BHPs in human immunodeficiency virus and acquired immune 
deficiency syndrome (HIV/ AIDS) prevention and sexually transmitted infections 
(STIs)/tuberculosis programs (Busia and Kasilo, 2010). 
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“International Conference on Promoting ecohealth Research in Africa: 
Towards the establishment of an African Chapter of ecohealth 
international” Programme 
13 and 14 November 2018 
 
Plenary - Day 1 
TIME  Activity  Presenter  Chair  
08:00-10:00 Registration  Secretariat  
10:00-10:30  Welcome Tea All  Professor Moses 
Chimbari 
 
 
 
 
10:30-11:00 Welcome, introduction of VIP and 
opening Address  
Professor Busi Ncama 
11:00-11:30 Role of Ecohealth in Current 
Global Health and Environmental 
Challenges 
Dr  Jonathan Sleeman 
11:30-11:50 Principles and general 
methodology of ecohealth 
Professor Moses Chimbari 
11:50-12:45 Lunch 
DAY 1 BREAKAWAY SESSIONS 
SESSION 1: MAIN HALL (THEME 1: ECOHEALTH AND EXPLOITATION OF NATURAL 
RESOURCES (MINING, AGRICULTURE AND TOURISM)) 
13:00-13:20 Contribution of forest ecosystem 
services towards food security 
and nutrition 
Cliff Dlamini Dr Cliff Dlamini 
13:20-13:35 Village chicken eggs used for 
sustainability to overcome food 
insecurity 
Thando Tenza 
13:35-13:50 A protocol for community-based 
forest enterprises: The case of 
non-timber forest products 
(NTFPs) 
Leyla Nkosi 
13:50-14:05 Occurrence of trypanosome 
infections in cattle in relation to 
season, livestock movement and 
management practices of Maasai 
pastoralists in Northern Tanzania 
Esther G. Kimaro 
14:05-14:20 Life history traits of Bulinus 
globosus, post resuscitation from 
aestivation 
Chester Kalinda 
14:20-14:35 Influence of distance to water 
source on productivity of Nguni 
weaners and does 
Cresswell Mseleku 
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14:35-14:50 Exploration of nutrient dense 
traditional dishes as a possible 
intervention for child malnutrition 
Maria Nnyepi 
14:50-15:05 Increasing the resilience to water-
related risks in the UK fresh fruit 
and vegetable system 
Mlungisi Shabalala 
15:05-15:10 Effects of decentralised 
wastewater treatment effluent on 
taro and banana, soil and the 
environment 
William Musazura 
15:10-15:25 Quorum sensing inhibitory 
potential of biologically-active 
compounds from Bulbine 
natalensis (Baker) 
Olusola Bodede 
15:25-15:40 Is plastics contamination a 
concern in Durban harbour? 
Refilwe Mofokeng  
15:40-15:55 Sanitation Safety Plans for the use 
of human excreta fertilizers in 
crop production 
Sharon Migeri 
15:55-16:10 Evaluating the use of recovered 
rutrients from a ultrafiltration 
membrane toilet effluent for crop 
production in urban agriculture 
Sisekelo Sihlongonyane 
Poster Presentation  
16:10-16:15 Can crocodile meal used for 
poverty alleviation? 
Rendani Luthada-Raswiswi  
SESSION 2: BREAKAWAY ROOM  (ECOHEALTH AND LOCAL KNOWLEDGE 
SYSTEMS-AN AFRICAN PERSPECTIVE) 
13:00-13:20 Ecohealth” approach in the 
control and prevention of 
Neglected Zoonotic Diseases-An 
African perspective 
Samson Mukaratirwa Dr Elizabeth 
Ojewole 
13:20-13:35 The cost implications of the 
National Health Insurance and 
traditional healing and medicine in 
South Africa 
Naseema Vawda  
13:35-13:50 Prevalence and risk factors of 
schistosomiasis and soil-
transmitted helminthiasis among 
preschool children aged (1-5 
years) in rural KwaZulu-Natal 
Hlengiwe Sacolo  
13:50-14:05 Ethno-botanical study on the 
indigenous knowledge on malaria 
in the Gwanda district, Zimbabwe 
Margaret Macherera 
14:05-14:20 Evaluation of concomitant use of 
prescribed antiviral, antibacterial 
and/or antifungal medicines with 
traditional medicine in Ilembe 
district, South Africa: A medical 
chart review 
Mukanda Gedeon 
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14:20-14:35 Village chicken eggs used for 
sustainability to overcome food 
insecurity 
Thando Tenza 
14:35-14:50 Exploitation of indigenous 
knowledge in controlling gastro-
intestinal nematodes in chickens 
Nkanyiso Majola 
14:50-15:05 Achieving EcoHealth principles 
through community engagement 
Rosemary Musesengwa 
15:05-15:20 Community engagement campaign 
toward a pilot small-scale 
mosquito sterile insect technique 
(SIT) release programme in Jozini 
KwaZulu-Natal, South Africa 
Thabo Mashatola 
15:20-15:35 Knowledge and documentation of 
patient health information 
amongst traditional health 
practitioners in urban and peri-
urban in Durban, KwaZulu-Natal 
province, South Africa 
Tracy Zhandire 
15:35-15:50 Up-regulation of hippocampal 
synaptophysin expression, GFAP 
cell count and mGluR3 
immunoreactivity in a pilocarpine 
rat model of epilepsy 
Oluwole Alese 
15:50-16:05 Molecular identification of 
hookworm isolates from stray 
dogs, humans and selected 
wildlife from KwaZulu-Natal and 
Mpumalanga provinces of South 
Africa. 
Philile Ncamphalala 
Poster Presentations  
16:20-16:25 Of women, goats, chickens and 
blankets: gender intersectionality 
insights from the Botswana 
Ecohealth Project  
Barbara Ntombi Ngwenya 
16:25-16:30 Combination anthelmintic therapy: 
an adaptation from nature 
Fomum Sylvester   
16:30-17:00 Afternoon tea 
17:00-18:30 FORMATION AND LAUNCH 
OF THE AFRICAN CHAPTER  
Professor Chimbari and Dr 
Sleeman 
Professor  Samson 
Mukaratirwa  
18:30-Late DINNER  
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